Final Programme

11 EACPT
th

Congress
28 - 31
August 2013
Geneva
Switzerland
EACPT Contents 3
2013

Welcome Message
4

Committees
5

General Information
6-8

Social Programme
9

Exhibitors & Sponsors

10

Awards and Recognition

11

Programme Overview
12-13

Plenary Speaker Biographies

14

Scientific Programme
16-28

Poster Presentations
29-43

Exhibition Floor Plan

44

Congress Centre Floor Plan

44-45

Congress Centre – Access Map

46
EACPT Welcome Message 4
2013

Dear
Colleagues
It is a great pleasure to welcome you to the 11th Conference
of the European Association for Clinical Pharmacology
and Therapeutics (EACPT) in Geneva. Under the auspices
of the Swiss Society of Clinical Pharmacology and
Toxicology and the other sponsors, the Congress will take
place from 28 to 31 August 2013 at the International
Conference Center Geneva (CICG), in the smallest of the
world class metropolis.

Clinical pharmacology provides a wide array of services,

from excellence in patient care, teaching and clinical
research to high standard efficient contribution in drug
development and professional services in regulatory bodies.

The Congress is a unique opportunity to meet top ranking

specialists of various professional backgrounds involved
in drug discovery, drug development, pharmacology and
pharmacotherapy teaching, drug use, drug epidemiology,
and drug safety.

I hope that the exciting topics proposed in the program

stimulate your interest.
Thank you for joining us in Geneva.

On behalf of the organizing committee,

Best Regards,

Professor Pierre Dayer, MD

Congress President
EACPT Committees 5
2013

National International
Organizing Advisory 
Committee Board

Congress President •
•
Dr. Nina Bjarnason, Denmark
Prof. Ylva Böttiger, Sweden
• Prof. Pierre Dayer, Geneva • Prof. Kim Brøsen, Denmark
• Prof. Gonzalo Calvo Rojas, Spain (EACPT chair)
• Prof. Ingolf Cascorbi, Germany
• Prof. Kari Kivistö, Finland (EACPT treasurer)
Co-Chairs • Prof. Simon R. J. Maxwell, United Kingdom
• Prof. Gerard Rongen, The Netherlands
• Dr Marie Besson, Geneva • Prof. Matthias Schwab, Germany
• Dr Caroline Samer, Geneva • Prof. Tabassome Simon, France (EACPT vice-chair)
• Prof. Donald Singer, United Kingdom (EACPT secretary)
• Prof. Edoardo Spina, Italy
• Prof. Zoltan Szekanecz, Hungary
Members • Prof. Adam Vas, Hungary
• Prof. Dinko Vitezic, Croatia
• Dr Edoardo Baglivo, Geneva • Prof. Theo de Vries, The Netherlands
• Dr. Marie Besson, Geneva • Prof. David Webb, United Kingdom
• Prof. Thierry Buclin, Lausanne
• Prof. Chantal Csajka, Lausanne
• Dr. François Curtin, Geneva
• Dr. Youssef Daali, Geneva
• Prof. Pierre Dayer, Geneva
• Prof. Jules Desmeules, Geneva
• Dr. François Girardin, Geneva
• Dr. Markus Hodel, La Chaux-de-Fonds
• Dr. Ilse Kern, Geneva
• Dr. Mitsuko Kondo Oestreicher, Geneva
• Prof. Dr. Gerd A. Kullak-Ublick, Zurich
• Dr. Hugo Kupferschmidt, Zurich
• Dr. Shanthi Narayan Pal, Geneva
• Dr. Caroline Samer, Geneva
EACPT General Information 6
2013

 Opening hours  Official language

of the registrations The sessions and congress materials will be available in
English. No interpretation nor translation will be provided.

Wednesday 28 August 2013 07:30 – 19:00

Thursday 29 August 2013

08:00 – 18:30  Certificate
Friday 30 August 2013

08:00 – 18:30 of Attendance
Saturday 31 August 2013 08:30 – 11:30 A Certificate of Attendance will be provided to you with your
congress materials if you pre-registered for the Congress.
For on-site registrants, a Certificate of Attendance will be
provided as quickly as possible but participants may be

 Opening hours asked to return at a quiet period to collect their certificate.

No certificates will be issued after the Congress.
of the exhibition

Wednesday 28 August 2013 10:00 – 17:30  Disabled persons

The CICG offers a full range of amenities to assist those
Thursday 29 August 2013 10:00 – 17:30
with disabilities. Lifts are also at the disposal for those with
disabilities. For further information or assistance please go
Friday 30 August 2013 10:00 - 17.30
to the Congress Information Desk on Level 0.

 Congress Venue  Use of cameras

All scientific sessions, poster presentations, industry
exhibition, coffee breaks and lunches will be located in the
and telephones
Centre International de Conference de Genève (CICG)
The use of any type of audio or visual recording equipment
see access plan page 46:
is not permitted during any of the scientific presentations.
This includes the use of video or digital cameras to record
17 rue de Varembé
speaker slide presentations. Cell/mobile phones must be
CH – 1211 Genève 20
on silent or diverted for all Congress sessions.

 Speakers  No Smoking
All speakers are asked to visit the Speaker Preview Room
The CICG is a smoke-free facility. No indoor smoking areas
located on Level 0, behind the “Bar Léman” (coffee bar),
are provided.
no later than two hours before their presentation.


Wednesday 28 August 2013

07:30 – 19:15
 Name badges
Thursday 29 August 2013 08:00 – 19:00 Security is strict in the CICG. You will need to wear your

delegate name badge at all times. This will identify you to
Friday 30 August 2013 08:00 – 19:00 Congress colleagues, door and catering staff. Delegates who

do not display the appropriate name badge will not
Saturday 31 August 2013 08:00 – 12:00 be permitted to enter the CICG. Lunch and coffee break
services will only be available to delegates registered for
the full Congress, or for that particular day.
EACPT General Information 7
2013

 Catering points  Computer terminals

Lunch will be served every day from the restaurant area on There are computer terminals available on Level 0 at the
Level 1. Coffee stations will be available in the exhibition venue for participants to use for internet access.
area on Level 0 of the CICG. For break times, please see
daily programme schedules.

 Programme Changes

 Cloakroom Organisers cannot assume liability for any changes in the

programme due to external or unforeseen circumstances.
A cloakroom service is available for participants on Level 0.
Please make sure that no personal belongings are left after
closing each day. All items are left at the owner’s risk.

 Congress bag
Opening hours:

We are pleased to announce that our EACPT 2013 delegate
Wednesday 28 August 2013 07:30 – 20:15
bag has been produced by Township Patterns, a social
Thursday 29 August 2013 08:00 – 20:00 enterprise which designs, produces and markets a range
of eco-friendly textile Congress bags in order to directly
Friday 30 August 2013 08:00 – 18:45 support the sustainable development of women-owned
sewing cooperatives operating out of the townships of
Saturday 31 August 2013 08:30 – 12:15 South Africa.
Township Patterns is a fair trade, WFTO ([Link])
accredited company and supplies customers world-wide.

 Emergency and

assistance on site  Registration Fees

In case of emergency, or if you require any assistance,
please contact the staff at the Information Desk on Level 0.
(on-site registrations)
A medical room is located on Level -1 and will be staffed by
medical personnel throughout the congress.
From 22
Registration Type
August 2013

 Poster Boards Congress Delegate

(Member of an affiliated society) 900 CHF

All poster boards are located on Level 0 of the CICG.
Poster Presenters are requested to hang their poster Congress Delegate
between 08:00 – 10:00 on Wednesday 28 August 2013. (Non-Member of an affiliated society) 950 CHF

All posters will be displayed for the duration of the congress.
Presenters are requested to leave their poster on display PhD Student 430 CHF

until 11.15 on Saturday 31 August 2013.
Presenters are responsible for removing their own poster. Qualified Participant
Any poster not removed by 12:30 on Saturday 31 August from Developing Countries 430 CHF

2013 will be removed and disposed of. No posters will be
retained by the organisers and/or returned to presenters. Day Ticket
(all categories) 350 CHF

Presenters are required to stand by their poster for their
Poster Guided Tour on the relevant day and time. Poster
guided tours will take place at the following times:

Wednesday 28 August 2013 12:30 – 13:30

Thursday 29 August 2013 12:30 – 13:30

Friday 30 August 2013 12:30 – 13:30

Saturday 31 August 2013 10:30 – 11:15
EACPT General Information 8
2013

 Liability and insurance  Organising Secretariat

Neither the organisers nor EACPT will assume any
responsibility whatsoever for damage or injury to persons EACPT 2013
or property during the Congress. C/o MCI Suisse SA
Rue de Lyon 75
P.O. Box 502
1211 Geneva 13

 Accommodation Switzerland

The hotel desk is located in the registration area on Level 0.

REGISTRATION & ACCOMMODATION
Please visit the hotel desk to make or amend a reservation
Tel: +41 22 33 99 725
during your visit to the Congress.
Email: eacpt2013reg@[Link]

 Registration fee for  Acknowledgements

regular participants The Organising Committees would like to acknowledge
and students includes the support of:

• Access to scientific presentations, poster presentations,

congress material, abstracts online
• Access to the exhibition
• Opening Plenary and Welcome Reception
(Wednesday 28 August 2013) World Health Organisation
• Daily lunches at congress venue (3 days)
• Coffee breaks
• Cultural event on Thursday evening
(29 August 2013 at the CICG)

 INTERNET
An internet corner is located in the exhibition area.
Wi-Fi connection is also available in the conference venue.
Wireless internet access is available to all participants in
the conference venue. Personal access codes are provided
together with the badge and here below:
Username: EACPT
Password: 2013
EACPT Social Programme 9
2013

 Welcome  Congress
Reception Dinner

Wednesday 28 August 2013 20:15 Friday 30 August 2013 20:00 – 22:30

Venue: CICG, Level 0 Venue: aboard the boat “Lausanne” – cruise on lake Geneva

Meeting point: Embarcadère des Pâquis
All registered participants are invited to join us directly Quai du Mont-Blanc
after the Opening Plenary for the Welcome Reception. (Front of the Beau-Rivage Hotel)
The reception will take place on Level 0 of the CICG.

Take this unique opportunity to join your colleagues and

peers from throughout Europe for an informal moment of
relaxation and the perfect chance to spend the evening

Cultural
aboard a cruise boat on the beautiful Lake Geneva. Enjoy

 drinks and a finger buffet whilst catching up with existing

acquaintances and meeting new ones. Entertainment

Event
will be provided by Swiss band “Recall”.

 Dress code: evening wear

Thursday 29 August 2013 19:00

Tickets are available from the
registration area - space is limited
Venue: CICG, Level 0
so don’t miss your opportunity
to participate in this evening !

For those of you visiting Geneva or Switzerland for the first

time, this will be the opportunity to get a taste of the Swiss
culture. Those of you who have visited before, don’t miss this
opportunity to sample some fine Swiss chocolate and enjoy
Alpine music with a modern twist. Participants will also be
able to purchase Swiss chocolates during the event. This
event is open to all registered participants.
EACPT Exhibitors and Sponsors 10
2013

 EACPT would like to thank the generous support

of the Exhibitors & Sponsors at the 2013 Congress:

SILVER BRONZE OTHERS

Almirall Gedeon Richter Astellas

Congress Bags & Lanyard Sponsorship Satellite Symposium Website Sponsorship

Società Italiana de Farmacologia Merck (Schweiz) AG

Satellite Symposium Delegate Bag Insert

Innovative Medicine Initiative (IMI) TRB Medica

Satellite Symposium Final Programme Advertising

Novartis Pharma Schweiz AG British Pharmacology Society

Exhibitor & Final Programme Satellite Symposia and Exhibitor
Advertising

Wiley
Exhibitor

EACPT Awards and Recognitions 11
2013

 EACPT 2013  EACPT Scientific Award

Poster Prizes: Dr David Devos
The EACPT congress will be awarding one Poster Prize per The EACPT is delighted to announce that the 2013 EACPT
day of CHF 1,000. The winning posters will be selected Scientific Award goes to Dr David Devos from the
amongst those accepted and presented at the congress. Department of Medical Pharmacology at the Université
All posters accepted and presented will be considered. Lille Nord, France. The EACPT Scientific Award is for the
Poster Prizes will be presented during the Closing Ceremony. report by Dr Devos of a new approach to treating Parkin-
son’s disease.

The paper, for which Dr Devos was corresponding author,

 EACPT Lifetime was published in the July 2012 issue of the high impact
international journal - Lancet Neurology, entitled:
Achievement Awards ‘Methylphenidate for gait hypokinesia
and freezing in patients with Parkinson’s
Prof Sir Michael Rawlins disease undergoing subthalamic
stimulation: a multicentre, parallel,
and Prof Carlo Patrono randomised, placebo-controlled trial.’

The 2013 Lifetime Achievement Award of the European The prize will be presented to Dr Devos
Association of Clinical Pharmacology and Therapeutics on Thursday 29 August during the
goes jointly to Professor Sir Michael Rawlins and to plenary session in Room 2 of the CICG,
Professor Carlo Patrono, for their outstanding contribu- Dr David Devos 11:45.
tions to the national and international benefits of clinical
pharmacology for medicine, health care and patient safety.

The awards will be presented

on Friday 30 August 2013  EACPT Special Award
during the plenary session
in room 2 of the CICG, 11:45.
Prof Michael Orme
The EACPT is delighted to announce a Special Award for
services to the EACPT for Professor Michael Orme.
Michael Orme was the first honorary secretary of EACPT
from 1995-2003, chairman of the Education Sub-committee
Professor
from 1997 to 2003, and chairman of EACPT from 2003-2007,
Sir Michael Rawlins
remaining on the Executive Committee as past chairman
until 2011.

In these roles Michael Orme brought his

interests in European and global efforts
of clinical pharmacology as a medical
speciality devoted to the rational use of
drugs, to growing EACPT into a major
international organisation representing
Professor all clinical pharmacology societies in
Carlo Patrono Europe.
Professor
Michael Orme The prize will be presented to Professor
Orme on Thursday 29 August during the
plenary session in Room 2 of the CICG,
11:45.
EACPT Programme Overview 12
2013

Wednesday 28 August 2013

 Room 2 Room 3 Room 4

09:00 - 10:30 Predictive Pharmacogenetics How to become a self-empowered patient Updates in clinical toxicology

10:30 - 11:00 Coffee Break

Special populations:
11:00 - 12:30 Clinical trials methodologies Networking in Clinical Toxicology
prenatal pharmacology

12:30 - 13:30 Lunch and Posters Guided Tour

The use of molecular imaging biomarkers in

13:30 - 15:00 Health therapies assessment Training tomorrow’s prescribers
drug development (EANM)

15:00 - 15:30 Coffee Break

Assessing and supporting tomorrow’s

15:30 - 17:00 Health issues and communication Health economic assessment
prescribers (BPS)

17:00 - 17:30 Break

Current trends in Global

17:30 - 18:30 Whats new in malaria therapeutics (WHO)
Pharmacovigilance (WHO)
Plenary: Innate immune sensing of nucleic
18:30 - 19:15 acids and application for oligonucleotide –
based immunotherapy

19:15 - 20:15 Opening ceremony

20:15 - 21:00 Welcome reception

Thursday 29 August 2013

 Room 2 Room 3 Room 4

Personalizing cancer therapy
09:00 - 10:30 New developments in TDM Pharmacovigilance networks (WHO)
(with ASCPT)

10:30 - 11:00 Coffee Break

Plenary: Anti-Angiogenic Therapy:

11:00 - 11:45
New Insights

11:45 - 12:00 EACPT Scientific and Special Awards

12:00 - 13:30 Lunch Lunch

Innovative Medicines Initiative
12:30 - 13:30 Posters Guided Tour Posters Guided Tour

Clinical trials regulation, Inflammatory disease Drug Safety: from clinical trials
13:30 - 15:00
control, benefits and Biotherapeutics to clinical practice (WHO)

15:00 - 15:30 Coffee Break

15:30 - 17:00 Frontiers in Pharmacology (BPS) Ocular Pharmacology Drug Safety in emerging countries (WHO)

17:00 - 17:30 Break

The dopamine D3 receptor as a potential

17:30 - 19:00 Pharmacology of Chocolate target for psychiatric diseases
(Gedeon Richter)

19:00 - 21:00 Chocolate tasting and cultural event

EACPT 13
2013

Friday 30 August 2013

 Room 2 Room 3 Room 4

09:00 - 10:30 Diabetes PK/PD modelling Who should initiate drug development?

10:30 - 11:00 Coffee Break

Plenary: Immune mechanisms

11:00 - 11:45
of atherosclerosis

11:45 - 12:00 EACPT Lifetime Achievement Awards

12:00 - 13:30 Lunch

12:30 - 13:30 Posters Guided Tour

13:30 - 15:00 Special cardiovascular pharmacology Ethics Special liver pharmacology

15:00 - 15:30 Coffee Break

Advances in the treatment of rare

15:30 - 17:00 Drug-drug Interactions diseases: expectations on advanced New targets for pain treatment
therapies

17:00 - 17:30 Break

Future Challenges for Clinical Methodological issues in clinical trials

17:30 - 19:00
Pharmacology in Health Care (WHO) with CNS drugs (SIF)

20:00 - 23:00 Gala dinner

Saturday 31 August 2013

 Room 2 Room 3 Room 4

Neuro-Psychopharmacology:
09:00 - 10:30 Best abstract, oral communications Doping: Sports and Pharmacologists
filling the gaps

10:30 - 11:00 Coffee Break and and Posters Guided Tour

11:15 - 12:00 Closing ceremony and poster awards

EACPT Plenary Speaker Biographies 14
2013

 Prof. Gunther  Prof. Ziad Mallat, M.D.

Hartmann, M.D. Dr. Mallat received his MD and qualification in Cardio-
vascular Diseases from University of Pierre et Marie Curie,
Gunther Hartmann studied medicine at the University in 1996, and his Ph.D. in Cardiovascular Physiology from
of Ulm. From 1994 to 1997, he worked as medical doctor University of Paris-Diderot in 1999. He joined INSERM,
at the University Hospital in Munich, Germany. In 1998 Paris in 1998 as Assistant Research Professor, then became
and 1999 he was postdoc in the laboratory of Arthur Krieg Associate Professor in 2002 and Research Professor in 2007.
at the University of Iowa, USA. Back in Munich he became He is currently BHF Professor of Cardiovascular Medicine
assistant professor at the Department of Clinical Pharma- at the University of Cambridge, UK. He is on the Editorial
cology of the University of Munich where he established Board of Circulation Research and Journal of Molecular
his research group Therapeutic Oligonucleotides. In 2005, Medicine, and is Associate Editor of Arteriosclerosis
he became head of Clinical Pharmacology of the University Thrombosis and Vascular Biology. He served from 2004
Hospital of Bonn. Since 2007, he is Director of the Institute to 2008 as a scientific advisor to the General Director of
of Clinical Chemistry & Clinical Pharmacology and the INSERM, France. He is co-founder and consultant for
Central Laboratory in Bonn. Gunther Hartmann has been ATEROVAX, a biopharmaceutical company.
continously working in the field of oligonucleotides since
1995. Major contributions were the characterization of Dr. Mallat has authored more than 100 scientific papers
the immunostimulatory activities of CpG oligonucleotides in peer-reviewed journals including New England Journal of
in the human immune system, the application of CpG Medicine, Nature Medicine, Journal of Clinical Investigation,
oligonucleotides in animal tumor models, the analysis Journal of Experimental Medicine, Circulation and Circulation
of immunological activities of siRNA and the responsible Research. Dr. Mallat’s early work identified apoptotic death
receptor TLR7 (Nat Med 2005) and the identification within the atherosclerotic lesion as the major determinant
of 5´triphosphate RNA as the ligand of plaque-tissue factor activity. He then has been actively
for the cytosolic antiviral helicase RIG-I studying the cellular and molecular pathways involved
(Science 2006). His prime interests are in the regulation of the immuno-inflammatory response in
innate immunity, immune sensing atherosclerosis. Particularly, research from his laboratory
of nucleic acids, and the development has pointed to new major chemokine pathways involved
of oligonucleotides for the therapy of in monocyte/macrophage recruitment and accumulation
viral infections and cancer. He is into atherosclerotic lesions, and identified a critical role
Speaker of the DFG-funded Excellence for the regulatory arm of the adaptive T cell response in the
Cluster "ImmunoSensation". control of lesion development. He has shown that defective
clearance of apoptotic cells impairs the regulatory immune
response in atherosclerosis and accelerates lesion develop-
ment, suggesting an important interplay between innate
and adaptive immunity in promoting lesion development

 Prof. Napoleone Ferrara,

and progression. More recently, he has
identified a pathogenic role for mature B

M.D. cells in the development of atheroscle-

rosis. Current research activities address
the relation between autoimmune
Dr. Ferrara obtained his M.D. degree in 1981 from the
diseases and atherosclerosis, and the
University of Catania Medical School in Italy. After
role of the regulatory immune response
completing his postdoctoral research at the University of
in the prevention and/or treatment of
California at San Francisco, he joined Genentech Inc. in
plaque vulnerability.
1988. He spent nearly 25 years with the organization where
his work on the isolation, molecular cloning and biological
characterization of VEGF-A resulted in the development
of bevacizumab, the first anti-angiogenic agent to be
approved by the FDA for cancer therapy. His research
there also led to the development of ranibizumab, which
has been FDA-approved for the treatment of multiple
intraocular neovascular disorders.
In December 2012, Dr. Ferrara joined
the University of California, San Diego
as a Distinguished Professor of Pathology
and Senior Deputy Director for Basic
Sciences of the Moores Cancer Center.
He plans to continue his research focus-
ing on the biology of angiogenesis
and the identification of its regulators.
EACPT 15
2013
EACPT Scientific Programme 16
2013

09:30 Medication use: from leaflet to
e-learning
Valérie Piguet

 WEDNESDAY
10:00 How to govern a self-powered patient:

28 August
privacy and biopower
Sami Coll

2013

 Updates in clinical
Room 4 toxicology
Chairpersons:
Hugo Kupferschmidt, Gerald Rongen

09:00 – 10:30 09:00 Lipid emulsion as a new antidote -
current use, extension from lipophilic
local anesthetics to other drugs,

 Predictive and state of the art

Theodore C. Bania
Room 2 Pharmacogenetics
09:30 Challenges in paracetamol poisoning
Chairpersons: Nicholas Bateman
Jules Desmeules, Ingolf Cascorbi
10:00 New insights into the mechanisms
09:00 Genetics of treatment response of dioxin toxicity in humans
in depression Jean-Hilaire Saurat
Antonio Drago

09:30 Pharmacogenetic and other factors COFFEE BREAK
in individualization of oral anti-vitamin k 10:30 – 11:00
anti-coagulants
Philippe Beaune

10:00 A promising predictor for heart diseases
and diuretic drug therapy in the

aldosterone receptor gene
11:00 – 12:30
Nawar Dalila

10:15 CYP2R1 genetic polymorphisms are
associated with lower 25-hydroxy
 Clinical trials
vitamin D levels in Lebanese subjects Room 2 methodologies
Nathalie Zgheib
Chairpersons:
Thierry Buclin, Ylva Böttiger

11:00 Towards best reporting practices
 How to become a for clinical pharmacology trials
Room 3 self-empowered patient
Doug Altman

11:30 The future of modeling and simulation

Chairpersons:
approaches in drug development
Christine Cedraschi, Donald Singer
Marc Pfister

09:00 Collection and impact of patient
reported outcomes
Anne Viola
EACPT Scientific Programme → WEDNESDAY 28 August 2013 17
2013

12:00 Biases on the administered parenteral
doses of an experimental drug during 
phase I clinical trials
13:30 – 15:00
Nicolas Widmer

12:15 Critical review of the validation process
of six predictive biomarkers: how good is
 Health therapies
the quality and quantity of the evidence?
Joaquin Saez Penataro
Room 2 assessment
Chairpersons:
Francois Girardin, David Webb


 Special populations: 13:30 The role of the clinical pharmacologist
Room 3 prenatal pharmacology in pharmacoeconomics, health
economics
Chairpersons: Michael Rawlins

Victoria Rollason, Gerard Rongen
14:00 The Scottish model: Scottish Medicines
Consortium (SMC)

David Webb
11:00 TINN (Treat Infections In Neonates) :
an FP7 project 14:30 An assessment of the accuracy
Evelyne Jacqz-Aigrain of horizon scanning predictions
of medicine use in the scottish national
11:30 Studying teratogenic effects of health service
medication use during pregnancy: Sharon Hems
challenges and pitfalls
Marleen van Gelder 14:45 Dabigatran - demonstrates the need
for comprehensive approaches
12:00 Pregnancy outcome following maternal to optimise the use of new drugs
exposure to mirtazapine: preliminary Brian Godman
results of a collaborative entis study
Ursula Winterfeld

12:15 Fetal exposure to nonsteroidal
antiinflammatory drugs and  Training tomorrow’s
spontaneous abortions Room 3 prescribers
Sharon Daniel
Chairpersons:
Simon Maxwell, Theo De Vries


 Networking in Clinical 13:30 The relevance of clinical workplace
Room 4 Toxicology learning and assessment in CP&T
Tim Dornan

Chairpersons: 14:00 A systematic follow-up of student-
Hugo Kupferschmidt, Gonzalo Calvo prescribers (track): therapeutic
knowledge, skills/competencies
and attitude
11:00 The poisons centres networks - David Brinkman
toxicosurveillance
Herbet Desel 14:30 Assessment of clinical pharmacology
skills as part of the new integrated final
11:30 Networking for regulatory toxicology exam for medical students at Karolinska
Martin Wilks Institutet
Marie-Louise Ovesjo
12:00 The Swiss model of comprehensive
antidote provision 14:45 The effect of a structured medical
Hugo Kupferschmidt record on the recording of therapeutic
information and communication
between doctors
LUNCH & POSTERS GUIDED TOUR Robert J. Van Unen
12:30 – 13:30
EACPT Scientific Programme → WEDNESDAY 28 August 2013 18
2013

 The use of molecular  Assessing and

Room 4 imaging biomarkers Room 3 supporting tomorrow’s
in drug development prescribers
(with the help of EANM) (sponsored by BPS)

Chairpersons: Chairpersons:
Christer Halldin, Adam Vas David Webb, Phil Routledge

13:30 Translational PET in Neuroscience 15:30 Development of a UK national
and Drug Development Prescribing Skills Assessment
Christer Halldin Simon Maxwell


14:00 The academia’s view on collaboration
16:00 Undergraduate training for medical
with industry
students in CPT and prescribing
Antony Gee
Sarah Ross
14:30 Opportunities and challenges
of molecular imaging collaboration 16:30 Electronic solutions for safer hospital
in pharmaceutical development prescribing
Paul Maguire Jamie Coleman

14:45 Interaction between industry 16:45 Developing a standardised prescription
and academia: Developing PET imaging chart to reduce error
tracer for Novel Targets Phil Routledge
Gilles Tamagnan

COFFEE BREAK
15:00 – 15:30  Health economic
Room 4 assessment
 Chairpersons:
Francois Girardin, Michael Rawlins
15:30 – 17:00

15:30 The economics of personalised medicine
and pharmacogenetic testing
 Health issues Dyfrig Hughes
Room 2 and communication
16:00 Value Based Pricing to ensure
Chairpersons: cost effective drugs for the UK NHS:
Pierre Dayer, Donald Singer will it work?
Mark Sculpher

15:30 Mediator (Benfluorex), a French and 16:30 Patented drug extension strategies on
worldwide public health disaster healthcare spending: a cost-evaluation
Irène Frachon analysis
Nathalie Vernaz
16:00 Risk perception among healthcare
professionals and the public: experience 16:45 Pharmacoeconomic drivers
from regional medicines information in pharmacogenomics
and pharmacovigilance centres in Stijn Vandekerckhove
Norway
Jan Schjott
BREAK
16:30 The risk–benefit relationship as a moral 17:00 – 17:30
compass
Michel Lievre
EACPT Scientific Programme → WEDNESDAY 28 August 2013 19
2013

 
17:30 – 18:30 18:30 – 20:15

 Whats new in malaria  Plenary: Innate immune

Room 3 therapeutics Room 2 sensing of nucleic acids
(sponsored by WHO) and application for
Chairperson:
oligonucleotide – based
Andrea Bosman immunotherapy
Günter Hartmann
17:30 Update on the status of artemisinin
resistance Chairperson:
Pascale Ringwald Pierre Dayer

18:00 New medicines for control
and elimination of malaria
Timothy Wells
 Opening ceremony
Room 2 Pierre Dayer, Congress President
Gonzalo Calvo, EACPT chair

 Current trends in Global Filippo Drago, EPHAR chair

Sandrine Salerno, Maire de Genève
Room 4 Pharmacovigilance
(sponsored by WHO)

Chairperson:

Lembit Rägo 20:15 – 21:00

17:30 Safety Information today and how can
we improve patient safety tomorrow  Welcome reception
Andrzej Czarnecki
Exhibition and poster area
18:00 Population pharmacogenetics and its
implications for pharmacovigilance
Adrian Llerena


17:30 – 19:00 Kindly offered by the Republic
and Canton of Geneva and the City
of Geneva

 SSCPT GS Meeting
Room 13 Private meeting
EACPT Scientific Programme 21
2013

 New developments
in TDM
THURSDAY
Room 3

 Chairpersons:

29 August
Thierry Buclin, Ylva Böttiger

2013
09:00 Monitoring drug therapy:
TDM-te deum or tedium?
Jeffrey Aronson

09:30 Strategies for the development of TDM
for targeted anticancer agents
Thierry Buclin

 10:00 A simplified method for busulfan

therapeutic drug monitoring using dried
08:00 – 09:00 blood spot sampling in pediatric patient
undergoing stem cell transplantation
Chakradhara Rao Uppugunduri

 Author’s Workshop 10:15 Clinical usefulness of therapeutic
Room 5-6 How to publish your concentration monitoring for imatinib
dosage individualization: results from
paper in a scientific the randomized controlled i-come trial
journal Verena Gotta

Chairperson:
Richard Shader, Editor-in-chief,
Clinical Therapeutics

 Pharmacovigilance
Room 4 networks
 (Sponsored by WHO)
09:00 – 10:30
Chairpersons:
Lembit Rägo, Shanthi Pal

 Personalizing cancer
Room 2 therapy 09:00 ENCEPP: Strengthening methodology,
transparency and independence
(Session co-organized with the Henry Fitt
American Society of Clinical
Pharmacology and Therapeutics 09:30 WHO Programme for International Drug
Monitoring
ASCPT) Shanthi Pal

Chairpersons: 10:00 What is the additional value of electronic
Caroline Samer, Matthias Schwab medical records for drug safety signal
detection? The experience of EU-ADR
project
09:00 The individualisation of cancer therapy Gianluca Trifiro
in organ dysfunction
Michelle Rudek
COFFEE BREAK
09:30 Targeted therapies in hematological 10:30 – 11:00
malignancies
Raymond Hohl

10:00 Personalized therapy in breast cancer
Matthias Schwab
EACPT Scientific Programme → thursday 29 August 2013 22
2013

 
11:00 – 12:00 13:30 – 15:00

 Plenary: Anti-Angiogenic  Clinical trials regulation,

Room 2 Therapy: New Insights Room 2 control, benefits
Napoleone Ferrara
(with the help of the Spanish Society
of Clinical Pharmacology)
Chairperson:
Gonzalo Calvo Chairpersons:
Emilie Alirol, Gonzalo Calvo

EACPT Scientific
13:30 Introductory remarks to the revision
and Special Awards of the EU Clinical Trials regulation
Gonzalo Calvo
(from 11:45)
13:45 The clinical researcher view:
David Devos, Michael Orme
Ideas for improvement
Cristina Avendaño


14:30 Clinical and non-interventional trials
LUNCH & POSTERS GUIDED TOUR
assessment in Croatia
12:00 – 13:30
Dinko Vitezic

14:45 The number of included older people

 in recent pre-autorisation trials

Erna Beers
12:00 – 13:30

 Innovative Medicines

Room 3 Initiative  Inflammatory disease

(Sponsored by IMI)
Room 3 and Biotherapeutics
Chairpersons:
Chairpersons:
Francois Curtin, Edoardo Spina
Elisabetta Vaudano, Adam Vas


13:30 New targets in the treatment
12:00 IMI: A Public Private Partnership
of rheumatoid arthritis
approach to the boosting
Zoltán Szekanecz
of pharmaceutical R&D

Elisabetta Vaudano
14:00 Multiple Sclerosis - New chances ?

François Curtin
12:15 Creating new models for R&D in areas

of unmet clinical need: Autism Spectrum
14:30 Up-titration study with ponesimod,
Disorder
a selective s1p1 receptor modulator,
Will Spooren , Roche
to assess its maximum tolerated dose

in healthy subjects
12:40 Addressing the challenges of diabetes
Matthias Hoch
and its complication: The IMI Diabetes

Platform
14:45 Off-label use and adverse events
Bernd Jablonka, Sanofi
of biologic agents in paediatric patients

with juvenile idiopathic arthritis
13:05 A PPP approach to boost antimicrobial
Julie Broe
resistance R&D: the ND4BB IMI platform
Seamus O’Brien, Astra Zeneca
EACPT Scientific Programme → thursday 29 August 2013 23
2013

 Drug Safety:  Ocular Pharmacology

from clinical trials to Room 3
Room 4 clinical practice Chairpersons:
Edoardo Baglivo, Zoltan Szekanecz
(Sponsored by WHO)

Chairpersons: 15:30 Anti-TNF in ocular diseases
Lembit Rägo, Shanti Pal Ildiko Süveges

16:00 Non infectious intermediate
13:30 CIOMS-From clinical trials to clinical and posterior uveitis: treatement and
practice-recent development place of local corticosteroids
Gunilla Sjölin-Forsberg Massimo Accorinti

14:00 The New Zealand centre for adverse 16:30 Interferon alpha and posterior uveitis
drug reactions monitoring: a source of Christine Fardeau
practice-based evidence
Ruth Savage 16:45 Sjögren ocular disease treatment
László Modis
14:30 Regulatory decisions and drug safety –
views from an agency outside EU
Rudolf Stoller


COFFEE BREAK  Drug Safety in emerging
15:00 – 15:30 Room 4 countries
(Sponsored by WHO)

 Chairpersons:
Lembit Rägo, Shanthi Pal
15:30 – 17:00

15:30 Drug safety in emerging countries -

 Frontiers in a perspective from Nigeria

Ambrose Isah
Room 2 Pharmacology
16:00 Latin-American pharmacovigilance
(Sponsored by BPS) update report: a quick overview
Mariano Madurga Sanz
Chairpersons:

Mounir Pirmohamed, Mark Caulfield
16:30 Overview of pharmacovigilance
in resource limited settings:

challenges and opportunities
15:30 Novel clinical trial designs for assessing
Sten Olsson
the efficacy of drugs
Max Parmar


BREAK
16:00 Novel biomarkers of drug-induced liver
17:00 – 17:30
injury
Kevin Park

16:30 Advances in genomics of blood
pressure - time for translation

Mark Caulfield 16:00 – 19:00

 EACPT Council Meeting

Room 5-6 Private meeting
EACPT Scientific Programme → thursday 29 August 2013 24
2013

 
17:30 – 19:00 19:00 – 21:00

 Pharmacology  Chocolate tasting

Room 2 of Chocolate and cultural event
Chairperson:
Exhibition and poster area
Jules Desmeules

With the participation of
17:30 Chocolate: pleasure for health
Claude Pichard
• Stettler
Jeremy Ramsauer
[Link]

• Merigonde
[Link]
 The dopamine D3
Room 3 receptor as a potential • Paganel
[Link]
target for psychiatric
diseases • Cartier
[Link]
(sponsored by Gedeon Richter)
Entertainment by Hornroh
Chairpersons:
Gerhard Gründer, Adam Vas

17:30 Antagonists and partial agonists
at D2 and D3 dopamine receptors
in psychiatric disorders: the spectrum
of therapeutic options
Gerhard Gründer

17:50 The functional role of D2 versus D3
dopamine receptors in health and
disease
Peter Gmeiner

18:10 Imaging the dopamine D2 and dopamine
D3 receptors in the living brain
Ilan Rabiner

18:30 A D3/D2 partial agonist antipsychotic
with preferential D3 binding on the
horizon
István Laszlovszky

18:50 Concluding remarks
Gerhard Gründer

 SSPM general assembly

Room 13 Private meeting
EACPT Scientific Programme 25
2013

10:00 Intrapulmonary pharmacokinetics and the
intracellular disposition to support the

FRIDAY
long-lasting efficacy after an inhaled

 administration of its prodrug laninamivir

octanoate

30 August
Kaoru Toyama

10:15 Optimal sampling strategy for busulfan
in stem cell transplantation patients

2013
Francine Castro

 Who should initiate

Room 4 drug development?
Chairpersons:
 Oliver Hartley, Adam Vas

09:00 – 10:30
09:00 Industry is more fit for clinical trials than
academy

 Diabetes
09:30
Adam Vas

Academia isn’t so bad either

Room 2
Chairpersons: Nicholas Moore

Markus Hodel, Matthias Schwab 10:00 Clinical trials registry and good clinical
practice: an indian scenario
Bikash Medhi
09:00 Novel antidiabetics: should they be used
at all - and in whom? 10:15 Interchangeability of gabapentin generic
Christoph Meier formulations in The Netherlands:
a comparative bioavailability study
09:30 Diabetes, diabetes risk factors and Marc Maliepaard
treatments, and breast cancer
Peter Boyle
COFFEE BREAK
10:00 Do treatment quality indicators predict 10:30 – 11:00
cardiovascular outcomes in patients with
diabetes?
Grigory Sidorenko 
11:00 – 12:00
10:15 Addressing the challenges of diabetes
and its complication: the IMI diabetes
platform
Bernd Jablonka  Plenary:
Immune mechanisms
and atherosclerosis
 PK/PD modelling Ziad Mallat
Room 3
Chairpersons: Chairperson: Hugo Kupferschmidt
Chantal Csajka, Kim Brøsen

EACPT Lifetime
09:00 The role of modelling and simulation
in clinical pharmacology Achievement Awards
Kayode Ogungbenro (from 11:45)

09:30 Quantifying the impact of nevirapine Sir Michael Rawlins, Carlo Patrono
based prophylaxis strategies to prevent
mother-to-child transmission of HIV-1
using the population approach LUNCH & POSTERS GUIDED TOUR
Charlotte Kloft 12:00 – 13:30
EACPT Scientific Programme → friday 30 August 2013 26
2013

 14:00 Acetaminophen-induced liver injury
in experimental animals and humans
13:30 – 15:00 Hartmut Jaeschke

14:30 Assessment of drug-induced liver injury

 Special cardiovascular from clinical trial data

Michael Merz
Room 2 pharmacology

Chairpersons: COFFEE BREAK
Jean-Luc Reny, Tabassome Simon 15:00 – 15:30

13:30 Clinical drug development of new
anticoagulants: a lesson of modern
clinical pharmacology

Patrick Mismetti
15:30 – 17:00

14:00 Novel approaches in the treatment
of dyslipidaemias
Anton F Stalenhoef
 Drug-drug Interactions
Room 2
14:30 Reversal strategy in antagonizing Chairpersons:
the P2Y12-inhibitor ticagrelor Youssef Daali, Kim Brøsen
Eva-Luise Hobl

14:45 Impact of circulating levels of 15:30 Complexity of predicting the magnitude
interleukin-17 and cardiovascular of drug-drug interactions in an individual
outcomes in patients with acute patient: this cannot fit to a pocket guide;
myocardial infarction ipad may be!
Tabassome Simon Amin Rostami-Hodjegan

16:00 Role of membrane transporters in drug
interactions
Mikko Niemi

 Ethics 16:30 Interaction between mycophenolate
mophetil and tacrolimus in kidney graft
Room 3
recipients
Chairpersons:
Jan Strojil
Ingolf Cascorbi, Philippe Ducor

16:45 Gemfibrozil impairs imatinib absorption

and inhibits the CYP2C8-mediated
13:30 Ethics and Privacy of Biobanks
formation of its main metabolite in
Berenice Elger
healthy volunteers

Anne M Filppula
14:00 Public health genomics and personalized
healthcare
Angela Brand

 Advances in the
Room 3 treatment of rare
 Special liver
diseases: Expectations
Room 4 pharmacology
on advanced therapies
Chairpersons:
Gerd Kullak, Kari Kivisto Chairpersons:
Ilse Kern, Gonzalo Calvo

13:30 Immunological aspects of drug
hypersensitivity – from molecule to man 15:30 New developments in the treatment
Kevin Park of Inborn Errors of Metabolism
Matthias Baumgartner
EACPT Scientific Programme → friday 30 August 2013 27
2013

16:00 Treating rare inborn errors of
metabolism: from theory to practice

Matthias Gautschi 17:30 – 19:00

16:30 Gene therapy approval process at EMA
Sol Ruiz
 Future Challenges for
Room 2 Clinical Pharmacology

in Health Care
 New targets for pain (Sponsored by WHO)
Room 4 treatment
Chairpersons:
Chairpersons: Lembit Rägo, Folke Sjöqvist
Jules Desmeules, Dinko Vitezic

17:30 The background to the new WHO/
15:30 Targets for drug development in HIV IUPHAR/CIOMS manifesto entitled
neuropathy “Clinical Pharmacology in Health Care,
Andrew Rice Teaching and Research” and the
importance of the focus on health care
16:00 Transient receptor potential channels Folke Sjöqvist
as novel drug targets
Pierangelo Geppetti 18:00 Historical development and current state
of Clinical Pharmacology in Russia
16:30 Dual reuptake inhibitor milnacipran and Ksenia Zagorodnikova

spinal pain pathways in fibromyalgia 18:30 Clinical Pharmacology in Healthcare
patients: a randomized double-blind in Croatia
placebo-controlled trial Vera Vlahovic-Palcevsk
Alain Matthey

16:45 A new pharmaceutical form of
paracetamol : efficacy of transmucous  Methodological issues
buccal paracetamol in acute pain Room 3 in clinical trials with CNS
patients
Gisele Pickering drugs
(Sponsored by Italian Society

BREAK
of Pharmacology)
17:00 – 17:30
Chairpersons:
Pier Luigi Canonico, Edoardo Spina


17:30 Clinical trials in epilepsy
17:00 – 19:00 Emilio Perucca

18:00 Clinical trials in neuropathic pain
Soren Sindrup
 EACPT Executive
18:30 Clinical trials in schizophrenia
Room 5-6 committee meeting Wolfgang Fleischacker

Private meeting

20:00 – 23:00
GALA DINNER

Bateau "Le Lausanne"

Embarcadère des Pâquis, Quai du Mont-Blanc
(Front of the Beau-Rivage Hotel)

Tickets must be paid separately –

see page 9 for more details
EACPT Scientific ProgrammE 28
2013

 Doping: Sports
and Pharmacologists
Saturday
Room 3

 Chairpersons:

31 August
Mitsuko Kondo, Martial Saugy

09:00 Development of partnerships between

2013 the biopharmaceutical industry

and the world anti-doping agency
Olivier Rabin

09:30 Doping in sport: The biomarkers are
the best tools to measure its prevalence
and to establish the individual
monitoring of the athletes

Martial Saugy
09:00 – 10:30 10:00 The makings of the world-class athlete:
physiologic, genetic, psychosocial
and economic determinants

 Best abstract, Yannis Pitsiladis

Room 2 oral communications

Chairpersons:
Pierre Dayer, Gonzalo Calvo  Neuro-Psychopharmacology:
Room 4 filling the gaps

09:00 Generic substitution of antiepileptic Chairpersons:
drug (AED) and loss of seizure control: Marie Besson, Edoardo Spina
a population-based case-crossover
study
Elisabeth Polard 09:00 Prediction of pharmacological effects
of CNS-active agents during early
09:15 Parenteral Busulfan in Myeloablative phases of drug development
conditioning regimens for hematopoietic Joop Van Gerven
stem-cell transplantation (HSCT)
in children 09:30 New strategies in the treatment
Daniela Janeckova of major depression
Francesc Artigas

09:30 Cedia assays for buprenorphine,
10:00 Sleep quality of chronic benzodiazepine
methadone and EDDP in urine – simple
users in nursing homes: a comparative
methods, but sufficient for the purpose?
study with non-users
Jon Berg
Jolyce Bourgeois

09:45 Target gene evaluation of two miRNAs 10:15 Indications and dosages of atypical
differently expressed in focal and antipsychotics in Belgian nursing homes
non-focal brain tissue of therapy-resistant Majda Azermai
epilepsy patients
Sierk Haenisch
COFFEE BREAK AND POSTERS GUIDED TOUR
10:00 Self-empowering patients – a promising  10:30 – 11:15
example in oral anticoagulation
Stefan Vormfelde

10:15 Impact of CYP2C9 polymorphisms 
on the vulnerability to pharmacokinetic 11:15 – 12:00
drug-drug interactions during
acenocoumarol treatment
Victoria Rollason
Closing and poster
ceremony awards
EACPT 29
2013 Poster Presentations


 PP009
Poster Guided Tour DEVELOPMENT, VALIDATION AND USABILITY
OF SOFTWARE TO CALCULATE THE DRUG BURDEN
INDEX: A PILOT STUDY
L. Kouladjian* (AU) - D. Gnjidic - T. Chen - S. Hilmer

wednesday  PP010
MEDICATION SELF-ADMINISTRATION

28 August
IN HOSPITALISED PATIENTS: AN EVALUATION
USING DATA FROM AN ELECTRONIC PRESCRIBING
AND MEDICATION ADMINISTRATION SYSTEM

2013
S. J. Richardson - S. K. Thomas - S. E. McDowell - J. Hodson -
M. Afzal - U. Nwulu - J. J. Coleman* (GB)

 PP011
TIMELINESS OF MEDICINES ADMINISTRATION:

 12:30 – 13:30
USING DATA FROM AN ELECTRONIC PRESCRIBING
SYSTEM TO MONITOR THE QUALITY OF MEDICINES
PROVISION
S. K. Thomas* (GB) - I. Clark - L. Denner - J. J. Coleman
and Collaborations for Leadership in Applied Health
Research and Care for Birmingham and Black Country
 PP001 (CLAHRC-BBC) programme.
ADHERENCE AND SELF-REPORTED MEDICATION-
RELATED MORBIDITY: A POPULATION-BASED STUDY  PP012
K. Hedna* (SE) - S. Hägg - K. Andersson Sundell - NOT-IN-TRIAL SIMULATIONS: PREDICTING
M. Petzold - K. Hakkarainen CARDIOVASCULAR RISK FROM CLINICAL TRIALS

TO REAL LIFE CONDITIONS
 PP002 O. Della Pasqua* (GB) - A. Chain - J. Dieleman -
SEARCHING FOR HEALTH AND MEDICATION C. van Noord - A. Hofman - B. Stricker - M. Sturkenboom -
INFORMATION ON THE INTERNET. M. Danhof
A REVIEW OF THE LITERATURE
A. Jesaimini* (CH) - V. Rollason - C. Cedrashi - C. Luthy -  PP014
M. Besson - C. Boyer - J. A. Desmeules - V. Piguet PHARMACOLOGICAL INTERVENTIONS: A WAY TO

IMPROVE THE QUALITY OF ANTIBIOTIC USE
 PP004 P. Mas-Morey* (ES) - E. Sanmartin-Mestre - A. Ballesteros-
INCOMPLETE GENERIC SUBSTITUTION, Fernández - J. M. Bonell-Goytisolo - E. Alcoceba-Cruixent -
PATIENT CO-PAYMENT AND ADHERENCE C. Fuentes-Nieto
TO SSRIS IN ESTONIA
L. Rootslane* (EE) - O. Laius  PP015

CHRONOTHERAPY WITH DOCETAXEL, CISPLATIN,
 PP005 AND 5-FLUOROURACIL (5-FU) IN PATIENTS WITH
RISK PERCEPTION AND COMPLIANCE IN CHRONIC ORAL SQUAMOUS CELL CARCINOMA
MYELOID LEUKAEMIA PATIENTS TREATED WITH Y. Ioka* (JP) - K. Ushijima - T. Ioka - T. Noguchi - Y. JImbu -
TYROSINE KINASE INHIBITORS M. Kusama - A. Fujimura
K. Burdová* (CZ) - D. Friedecký - E. Faber - J. Strojil

 PP016
 PP006 EXPOSURE TO ANTIPSYCHOTICS WITH PRO-
CLINICAL DISINTEGRATION TIME AND VOLUME ARRHYTHMIC RISK: COMBINING ADVERSE DRUG
OF WATER REQUIRED FOR ORALLY DISINTEGRATING REACTIONS WITH DRUG UTILIZATION DATA
TABLETS IN HEALTHY VOLUNTEERS E. Raschi - E. Poluzzi - B. Godman* (GB) - A. Koci - I. Bishop -
S. Uchida* (JP) - T. Yoshita - S. Yagi - S. Hirata - T. Murao - M. Kalaba - O. Laius - U. Moretti - C. Sermet - M. Sturken-
S. Tanaka - N. Namiki boom - F. De Ponti

 PP008  PP017
DRUG-RELATED PROBLEMS IN A GENERAL SPECTRUM OF OCULAR DIGOXIN TOXICITY
INTERNAL MEDICINE SERVICE IN THE ELDERLY: A CASE REPORT
B. Guignard* (CH) - C. Samer - A. Perrier - P. Bonnabry - D. Renard* (CH) - E. Rubli - N. Voide - F.-X. Borruat -
P. Dayer - J. Desmeules L. Rothuizen
EACPT Poster Presentations → WEDNESDAY 28 August 2013 30
2013

 PP018  PP028
STORAGE AND WASTAGE OF ANTIBACTERIAL INFLUENCE OF PHARMACOLOGICAL EDUCATION
AGENTS IN HOUSEHOLDS IN NOVI SAD, SERBIA ON AWARENESS OF THE RISK OF ADVERSE DRUG
M. Paut Kusturica* (RS) - Z. Bukumiric - L. Ninkovic - REACTIONS
Z. Tomic - A. Sabo S. Mugosa* (ME) - Z. Bukumiric - D. Protic - Z. Todorovic

 PP020  PP029

EFFECTS OF ARIPIPRAZOLE AND RISPERIDONE PHARMACOVIGILANCE IN CRIMEA,

ON VENTRICULAR REPOLARIZATION IN CHILDREN UKRAINE IN 2012, ANNUAL REPORT
AND ADOLESCENTS O. V. Matvieiev* (UA) - O. I. Koniaieva - N. V. Matvieieva -
D. Italiano* (IT) - C. Privitera - L. Guerriero - A. Gagliano - P. M. Radzivil
M. Lamberti - R. Siracusano - E. Germanò - M. P. Calabrò -
E. Spina  PP031
DRUG-ASSOCIATED ACUTE LIVER FAILURE
LEADING TO REGISTRATION FOR
 PP022
TRANSPLANTATION IN FRANCE FROM THE STUDY
VARIATIONS IN DRUG-INDUCED LIVER INJURY
OF ACUTE LIVER TRANSPLANT (SALT)
(DILI) BETWEEN DIFFERENT PROSPECTIVE
DILI REGISTRIES E. Gulmez* (FR) - D. Larrey - G.-P. Pageaux - J. Jové -
R. Lassalle - S. Lignot - P. Blin - N. Moore
I. Medina-Cáliz - A. González-Jiménez - F. Bessone -

N. Hernández - A. Sánchez - M. Di Pace - M. Arrese -
J. R. Brahm - A. Ruíz - J. Arancibia - D. Kershenobich -  PP032
A. Loaeza - M. Girala - N. Mendez-Sanchez - M. Dávalos - ANTIDEPRESSANT PRESCRIPTION BY GAUTENG
M. Lizarzabal - E. Mengual - C. Stephens - M. Robles- DISPENSING DOCTORS
Díaz - R. J. Andrade - M. I. Lucena* (ES) S. Moch* (ZA) - S. Laher-Sibda - J. Miot

 PP023  PP033
HEMODIALYSIS FOR CEFEPIME INTOXICATION: EFFECTS OF PREGABALIN ON DRIVING
A CASE REPORT M. Nomoto* (JP) - T. Tsujii - W. T. Kyaw - N. Nishikawa -
L.-Y. Mani - S. Kissling - M. Burnier - T. Buclin - D. Renard* (CH) H. Iwaki - M. Nagai

 PP024  PP036

ADVERSE DRUG EVENTS AND MEDICATION ERRORS HEPATOTOXICITY IN ACUTE AND REPEATED
RELATED TO PSYCHOTROPIC DRUGS IN PATIENTS SUPRATHERAPEUTIC PARACETAMOL INGESTION
PRESENTING AT AN EMERGENCY DEPARTMENT IN CHILDREN AND ADOLESCENTS. RETROSPECTIVE
B. Pfistermeister* (DE) - H. Dormann - A. Patapovas - COHORT STUDY CONDUCTED BETWEEN 2005
F. Meier - F. Müller - A. Sonst - B. Plank-Kiegele - AND 2010
R. Vogler - O. Schöffski - T. Bürkle - R. Maas H. Y. Tong* (ES) - C. Zegarra - N. Medrano - A. Borobia -
A. Carcas - J. Frías - E. Ramirez


 PP025
 PP037
IMPROVING HY’S LAW DEFINITION TO BETTER
INJECTION OF PHARMACEUTICAL TABLETS
PREDICT THE RISK OF DEVELOPING ACUTE LIVER
OF BUPRENORPHINE: DIFFERENCES BETWEEN
FAILURE IN DRUG-INDUCED LIVER INJURY (DILI)
SUBUTEX® AND ITS GENERICS
M. Robles-Díaz* (ES) - C. Stephens - I. Medina-Cáliz -
R. Bouquié* (FR) - C. Victorri-Vigneau - J. Clouet -
A. F. González - A. González-Jiménez - E. Ulzurrun -
G. Deslandes - P. Jolliet-Evin
N. Kaplowitz - R. J. Andrade - M. I. Lucena

 PP038
 PP026
SOY DIET CAUSES HISTOLOGICAL CHANGES ON
MEDIGENIA: INNOVATIVE CLOUD BASED SOLUTION THE REPRODUCTIVE ORGANS OF ADULT MALE RATS
FOR PHARMACOVIGILANCE P. Papaioannidou* (GR) - T. Papamitsou - I. Kyriakidis -
S. Ussai* (IT) - A. Giordano - G. Trillò - R. Petelin - G. Giagnorio I. Makaronidis - I. Papaioannidis - N. Papadimitriou -
M. Dermentzopoulou

 PP027
DRUG-INDUCED LIVER INJURY DETECTED THROUGH  PP039
A PHARMACOVIGILANCE PROGRAM BASED IN DIFFICULTIES IN PHARMACOVIGILANCE PRACTICES
LABORATORY SIGNALS IN EUROPEAN NON-EU COUNTRIES AND THEIR
H. Y. Tong* (ES) - N. Medrano - C. Zegarra - A. Caparrós - DIFFERENCES FROM EU REQUIREMENTS
A. Borobia - J. Frías - E. Ramírez J. Vukovic* (RS) - N. Panjeskovic - O. Kypraios
EACPT Poster Presentations → WEDNESDAY 28 August 2013 31
2013

 PP040  PP053
DRUG INFORMATION UNIT – VALUABLE SOURCE CHALLENGES IN UNDERGRADUATE
OF INFORMATION, NOVI SAD EXPERIENCE PHARMACOTHERAPY EDUCATION:
S. Vukmirovic* (RS) - A. Sabo - Z. Tomic - V. Vasovic - THE GHENT UNIVERSITY EXPERIENCE
N. Stilinovic - A. Raskovic - B. Milijasevic - O. Horvat L. M. Van Bortel* (BE) and Pharmacotherapy Task Force

 PP042  PP054

SAFETY ASSESSMENT OF LOW DOSES OF METHA- PRESCRIBING COMPETENCE IN RELATION

DONE IN COMBINATION WITH BENZODIAZEPINES TO CONCEPTUAL AND CONTEXTUAL TEACHING
IN REAL OCCASIONS DURING METHADONE AND LEARNING
MAINTENANCE TREATMENT – A PILOT STUDY S. Moch* (ZA)

V. Mijatović* (RS) - A. Dickov - S. Petković - T. Popov -
I. Samojlik  PP055
PERSISTENT FEVER IN A WOMAN
FOLLOWING RIGHT KNEE HEMIARTHROPLASTY
 PP043
P. C. Eng* (GB) - D. Dworakowska
THE INFLUENCE OF HE EDUCATIONAL
AND ADMINISTRATIVE MEASURES
ON THE TREND OF USE OF UTEROTONICS  P057
THE OPERATIONALIZATION OF ELECTRONIC INN
O. Horvat* (RS) - N. Zeljkovic - M. Paut Kusturica -
PRESCRIBING
M. Ban - A. Sabo
E. Van Bever* (BE) - V. J. Wirtz - M. Azermai - G. De Loof -
T. Christiaens - L. Nicolas - L. Van Bortel - R. Vander
 PP044 Stichele
TOXICOLIST – A WEB-SERVICE TO IMPROVE
PATIENT-SAFETY  PP058
J. Ahlner* (SE) - H. Druid NEW MEDICINES AND DEVELOPMENT STRATEGIES
NECESSITATES CHANGE IN LIFELONG EDUCATION
OF CLINICAL PHARMACOLOGY
 PP045
THE EFFECTS OF YARROW’S S. -.- Kerpel-Fronius* (HU)

(ACHILLEA MILLEFOLIUM) HYDRO ALCOHOLIC
EXTRACT ON BLOOD PROTEINS IN MICE  PP060
M. Modaresi* (IR) - D. Dadkhah PATENTED DRUG EXTENSION STRATEGIES
AND HOSPITAL RESTRICTIVE DRUG FORMULARY:
A COST-EVALUATION ANALYSIS
 PP046
N. Vernaz* (CH) - G. Haller - F. Girardin - B. Huttner -
MEDICATION SELF-ADMINISTRATION C. Combescure - P. Dayer - D. Muscionico - J.-L. Salomon -
IN HOSPITALISED PATIENTS: AN EVALUATION P. Bonnabry
USING DATA FROM AN ELECTRONIC PRESCRIBING
AND MEDICATION ADMINISTRATION SYSTEM
 PP061
S. J. Richardson - S. K. Thomas - S. E. McDowell - J. Hodson -
RECENT REFORMS IN SCOTLAND TO TAKE
M. Afzal - J. J. Coleman* (GB)
ADVANTAGE OF GENERICS, THEIR INFLUENCE

AND IMPLICATIONS FOR HEALTH AUTHORITIES
 PP047 CONTEMPLATING FUTURE REFORMS
DO JUNIOR DOCTORS HAVE ENOUGH READY B. Godman* (GB) - I. Bishop - S. Campbell - J. Miranda -
KNOWLEDGE OF THE DRUGS THEY PRESCRIBE? M. Bennie

B. H.-E. Jansen* (NL) - G. W. Disselhorst - D. Brinkman -
J. Tichelaar - M. Richir - R. Unen, van - T. Vries, de  PP062
VARIABLE APPROACHES IN EUROPE
TO THE AVAILABILITY OF GENERIC LOSARTAN;
 PP048
IMPLICATIONS FOR THE FUTURE
A SYSTEMATIC REVIEW ON LEARNING
B. Godman* (SE) - M. Bennie - A. Bucsics - U. Hesse -
IN A STUDENT RUN CLINIC
A. Martin - J. Miranda - S. Simoens - C. Zara -
T. Schutte* (NL) - J. Tichelaar - R. S. Dekker -
L. L. Gustafsson
M. A. van Agtmael - M. C. Richir - T. P. G. M. de Vries

 PP063
 PP050 CHANGES IN THE UTILISATION OF VENLAFAXINE
SALIVA-BASED CYP1A2 PHENOTYPING USING AFTER THE INTRODUCTION OF GENERICS IN
CAFFEINE FROM BEVERAGES: A PRACTICAL SWEDEN: IMPLICATIONS FOR OTHER COUNTRIES
COURSE FOR STUDENTS B. Godman* (SE) - M. Persson - J. Miranda - B. Wettermark -
A. Jetter* (CH) - J. Mwinyi - C. Schaffner - G. A. Kullak-Ublick C. Barbui - L. L. Gustafsson
EACPT Poster Presentations → WEDNESDAY 28 August 2013 32
2013

 PP064
AGRANULOCYTOSIS DETECTION OUTCOME
BY CLOZAPINE TREATMENT (ADOC STUDY)
IN PSYCHIATRY: A COST-EFFECTIVENESS STUDY
F. R. Girardin* (CH) - A. Poncet - M. Blondon - V. Rollason -
N. Vernaz - P. Dayer - C. Combescure

 PP065
AN INVESTIGATION OF THE HORIZON
SCANNING APPROACH USED FOR NEW
MEDICINES IN THE SCOTTISH NATIONAL
HEALTH SERVICE
M. Bennie - J. Dear - E. Dunlop Corcoran - S. Hems* (GB) -
R. Newham - S. McTaggart - C. Waugh

 PP066
DO THE ANTIBIOTICS BOUGHT WITHOUT
PRESCRIPTION INFLUENCES THE TOTAL AMOUNT
OF ANTIBIOTICS?
O. Horvat* (RS) - V. Mijatovic - Z. Tomic - S. Vukmirovic -
A. Sabo

 PP068
A CROSS-SECTIONAL PILOT STUDY
ASSESSING NEEDS FOR AND ATTITUDES
TO IMPLEMENTATION OF INFORMATION
AND COMMUNICATION TECHNOLOGY
FOR RATIONAL USE OF MEDICINES AMONG
HEALTHCARE STAFF IN RURAL TANZANIA
J. Nilseng - L. L. Gustafsson - A. Nungu - P. Bastholm-
Rahmner - D. Mazali - B. Pehrson - J. Eriksen* (SE)

 PP069
ABCD(2) RISK SCORING IS NOT AN EFFECTIVE
TRIAGE TOOL FOR PREDICTING NEED FOR URGENT
TREATMENT IN PATIENTS WITH SYMPTOMATIC
CEREBRAL MICROEMBOLI OR CRITICAL CAROTID
ARTERY STENOSIS
M. Saedon - C. E. Hutcheson - C. Imray - D. R. J. Singer*
(GB) and Carotid Research Group

 PP070
HOSPITAL INFECTIONS IN INTERNAL MEDICINE
INTENSIVE CARE CLINIC: INCIDENCE, CAUSATIVE
AGENTS AND ANTIMICROBIAL CONSUMPTION
M. Miljkovic - N. Konstantinovic - A. Kovacevic* (RS) -
N. Rancic - V. Suljagic - B. Rakonjac - S. Vukotic -
V. Dragojevic-Simic

 PP072
URINARY TRACT INFECTIONS TREATMENT –
PRESCRIBING PATTERNS, GUIDELINES, AND LOCAL
RESISTANCE IN HEALTH CENTRE NOVI SAD
S. Vukmirovic* (RS) - O. Horvat - Z. Tomic - B. Milijasevic -
A. Sabo

 PP074
POTENTIAL EFFECT OF ALPHA-CHYMOTRYPCIN
ON GROWTH FACTORS IN ALZHEIMER’S DISEASE
MODEL
A. B. Shalby* (EG) - H. H. Ahmed - F. M. Metwally
EACPT Poster Presentations 33
2013


 PP083
Poster Guided Tour DABIGATRAN - DEMONSTRATES THE NEED FOR
COMPREHENSIVE APPROACHES TO OPTIMISE
THE USE OF NEW DRUGS
R. E. Malmstrom - B. Godman* (SE) - E. Diogene -

thursday
M. Bennie - J. Furst - I. Gutiérrez-Ibarluzea - L. McCullagh -
V. Vlahovic-Palcevski - L. L. Gustafsson

29 August
 PP084
A EUROPEAN SCORE PREDICTS BETTER
SOUTH AMERICAN CARDIOVASCULAR RISK

2013
THAN FRAMINGHAM RISK EQUATIONS
I. Marchant* (CL) - F. Gueyffier

 PP086
USAGE OF ANTIHYPERTENSIVE DRUGS IN SERBIA:

 12:30 – 13:30
AGE AND GENDER STRATIFICATION
A. Tomas* (RS) - O. Horvat - Z. Tomic - M. Ban - A. Sabo

 PP088
NITROSONIFEDIPINE, A PHOTODEGRADATION
PRODUCT OF NIFEDIPINE, SUPPRESS THE
PROGRESSION OF DIABETIC NEPHROPATHY
WITH THE ENDOTHELIAL DYSFUNCTION
 PP077 T. Sakurada* (JP) - K. Miyako - Y. Horinouchi - K. Teraoka -
ENDOTHELIAL DYSFUNCTION DUE TO ISCHEMIA- T. Kujime - K. Kawazoe - H. Houchi - T. Tamaki - K. Minakuchi
REPERFUSION INJURY IS NOT PREVENTED
BY METFORMIN THERAPY IN HEALTHY VOLUNTEERS
 PP090
S. Elmessaoudi* (NL) - T. Schreuder - R. Kengen -
THE 3.5-YEAR MORTALITY IMPACT OF DRUGS
D. Thijssen - G. Rongen - N. Riksen
IN SECONDARY PREVENTION OF MYOCARDIAL

INFARCTION IN REAL-LIFE (INTERIM ANALYSIS
 PP078 OF THE EOLE COHORT
COMPARISON OF A NEW ELISA-BASED C. Droz - C. Dureau - D. Thomas - N. Danchin -
WITH THE FLOW CYTOMETRIC ASSAY FOR J. Tricoire - J. Bénichou - F. Paillard - S. Hercberg -
VASODILATOR-ASSOCIATED STIMULATED I. Sibon - F. Rouanet - S. Rambelomanana - H. Maïzi -
PHOSPHOPROTEIN (VASP) PHOSPHORYLATION M.-A. Bernard - P. Blin - N. Moore* (FR)
TO ASSESS P2Y12-INHIBITION AFTER
TICAGRELOR INTAKE  PP091
E.-L. Hobl* (AT) - B. Jilma - U. Derhaschnig - COMPLEX REGULATION OF ALPHA-ADRENOCEP-
C. Schoergenhofer - M. Schwameis - P. Jilma-Stohlawetz TOR-MEDIATED VASOCONSTRICTION IN HUMAN
INTERNAL THORACIC ARTERIES
 PP080
L. E. Wilkins* (GB) - J. Watkins - A. Marsh - D. R. J. Singer
and Personalised Medicines Group
THE ROLE OF THE KCNJ5 POTASSIUM CHANNEL

VARIANTS IN ALDOSTERONE RELEASE
G. Massimo* (GB) and [Link],M. Stowasser,  PP092
K. O’Shaughnessy CHANGES IN VASCULAR REACTIVITY CAUSED
BY ANGIOTENSIN II IN ISOLATED VESSELS OF RAT
AORTA IN A MODEL OF HYPERTENSION
 PP081
E. M. Lopez-Calderon* (MX) - L. N. Acevedo-Villavicencio -
EVALUATION OF HYPOGLYCEMIC ACTIVITY G. C. Villanueva-Lopez - E. Lara-Padilla - G. Guevara-
OF A NOVEL LONG ACTING INSULIN ANALOGUE Balcazar - E. Hong-Chong - M. C. Castillo-Hernandez
M. Pawłowska* (PL) - M. Bogiel - K. Sitarek - J. Gromadzińska -
M. Bujalska-Zadrożny - A. Heinze - P. Borowicz

 PP094
TARGETS OF THERAPY OF PATIENTS WITH
 PP082 CONGESTIVE HEART HEART FAILURE CAUSED
PRESCRIPTION OF RECOMMENDED DRUGS BY ISCHEMIC HEART DISEASE AND DIABETES
FOR ACUTE MYOCARDIAL INFARCTION IN ESTONIA I. I. Megreladze - N. V. Gongadze* (GE) - T. D. Kezeli -
IN 2001 VS 2007 AND IN 2007 VS 2011 K. S. Kakabadze - M. G. Mirziashvili - Z. V. Chapichadze -
T. Marandi* (EE) - M. Blöndal - A. Tiia - J. Eha G. V. Sukoyan
EACPT Poster Presentations → THURSDAY 29 August 2013 34
2013

 PP098  PP114
NICORANDIL INDUCED ENDOTHELIUM-INDEPEN- SUNITINIB DOES NOT REDUCE ENDO-THELIUM-
DENT RELAXATION OF ARTERIAL BYPASS GRAFT DEPENDENT VASODILATION IN HUMANS
M. Marinko* (RS) - A. Novakovic - I. Stojanovic - P. Milojevic - A. Thijs* (NL) - W. T. van der Graaf - C. M. van Herpen -
M. Jovic - D. Nenezic - N. Ugresic - V. Kanjuh - Q. Yang - G. A. Rongen
G.-W. He

 PP115
 PP100 LOSS OF NFKB ACTIVITY DECREASES HEAT
POTENTIAL OF NATTOKINASE AS AN SHOCK PROTEIN LEVELS IN PANCREATIC
ANTITHROMBOTIC & FIBRINOLYTIC AGENT CANCER CELLS
T. Shirole* (IN) - S. L. Sharma - A. G. Jagtap U. Matsathit* (TH) - O. McGinn - V. Sangwan -
S. Banerjee - L. Phivthong-ngam - A. K. Saluja

 PP101
REACTIVITY MODIFICATIONS IN HEART RESISTANCE  PP116
VESSELS TO ANGIOTENSIN II IN ISOLATED METASTATIC BREAST CARCINOMA INDUCES
PERFUSED HEART OF HYPERTENSIVE RATS VASCULAR ENDOTHELIAL DYSFUNCTION
M. Lopez-Calderon* (MX) - L. N. Acevedo-Villavicencio - IN BALB-C MICE: ROLE OF TUMOR NECROSIS
G. C. Villanueva-Lopez - E. Lara-Padilla - G. Guevara- FACTOR-ALPHA AND NADPH-OXIDASE
Balcazar - E. Hong-Chong - M. C. Castillo-Hernandez S. Dalaklioglu* (TR) - A. Tasatargil - S. Kale - G. Tanriover -
S. Dilmac - N. Erin

 PP102
MOLECULAR DOCKING RESEARCH & IN-VITRO  PP117
ANALYSIS OF NOVEL NATURAL AND SYNTHETIC THE VARYING EFFECTS OF PENTOXIFYLLINE
PTP 1B INHIBITORS AS POTENTIAL THERAPEUTIC ON CYCLIN D1 LEVELS AND G1 PHASE ARREST
TARGET FOR DIABETES MELLITUS IN DIFFERENT RENAL CELL CARCINOMA CELL
D. Ahmed* (IN) MODELS
N. Mastrandrea* (US) - W. L. Cai - K. Y. Tham - T. J. Monks -
S. S. Lau
 PP103

EFFECTS OF CLOFIBRATE ON OUABAIN-INDUCED
ARRHYTHMIA IN ISOLATED RAT ATRIA  PP118
A. Bakhtiarian - S. Moradi* (IR) - V. Nikoui - F. Jazayeri IN VITRO STUDY OF SONODYNAMIC AND
PHOTODYNAMIC TREATMENT ON HUMAN

CANCER CELL LINES
 PP105 F. Foglietta* (IT) - R. Canaparo - A. Francovich - P. Civera -
THE ROLE OF POLY (ADP-RIBOSE) POLYMERASE L. Serpe
(PARP) PATHWAY ON ENDOTHELIN-1 (ET-1)-
INDUCED ENDOTHELIAL DYSFUNCTION IN RAT
THORACIC AORTA  PP119
B. Yilmaz - P. Sahin - E. Ordueri - C. Celik-Ozenci - EFFECT OF LIPOSOMAL CURCUMIN ON RED
A. Tasatargil* (TR) BLOOD CELLS IN VITRO
A. Storka* (AT) - B. Vcelar - L. Helson - M. Wolzt

 PP106
PREDICTORS FOR THE IMPROVEMENT OF LEFT  PP120
VENTRICULAR EJECTION FRACTION IN DILATED CHEMOTHERAPEUTIC ANTITUMOR ACTIVITIES
CARDIOMYOPATHY: RESULTS FROM A COHORT OF CURCUMIN
FROM THE CLINICAL COUNTY HOSPITAL CLUJ- A. M. El-Medany* (EG) - H. H. Hagar - O. A. Nayel -
NAPOCA J. M. El-Mednay
C. Pop* (RO) - E. Buzdugan - F. Loghin - C. Mogosan

 PP121
 PP107 CYP2C9 GENOTYPES ASSOCIATED WITH
CHRONIC TREATMENT WITH TAURINE AMELIORATES HIGHER SULFOLANE LEVELS IN CHILDREN
DIABETES-INDUCED DYSFUNCTION OF NITRIC RECEIVING INTRAVENOUS BUSULFAN
OXIDE-MEDIATED NEUROGENIC AND ENDOTHELIUM- PRIOR TO HEMATOPOIETIC STEM CELL
DEPENDENT CORPUS CAVERNOSUM RELAXATION TRANSPLANTATION
IN RATS C. R. S. Uppugunduri* (CH) - Y. Daali - M. A. Rezgui -
S. Dalaklioglu* (TR) - N. Kuscu - C. Celik-Ozenci - Z. Bayram - P. Huezo Diaz - A. K. Tyagi - J. Rousseau - M. Duval -
C. Nacitarhan - S. S. Ozdem H. Bittencourt - M. Krajinovic - M. Ansari
EACPT Poster Presentations → THURSDAY 29 August 2013 35
2013

 PP122  PP132
REGULATION OF HUMAN LEUKOCYTE ANTIGEN CONTRIBUTION OF GENETIC (CYP3A5, ABCB1 AND
EXPRESSION AND NEVIRAPINE-INDUCED ADVERSE POR) AND NON-GENETIC VARIABLES TO THE ORAL
DRUG REACTIONS IN A MALAWIAN HIV-POSITIVE TACROLIMUS CLEARANCE IN CHILDREN’S WITH
POPULATION STABLE KIDNEY TRANSPLANT, DURING ADVAGRAF®
E. M. Cornejo Castro* (GB) - D. F. Carr - V. A. Marshall - TREATMENT
M. Chaponda - S. Lane - A. Alfirevic - D. Whitby - G. N. Almeida-Paulo* (ES) - R. Lubomirov - N. L. Alonso-
M. Carrington - M. Pirmohamed Sanchez - L. Espinosa - A. J. Carcas

 PP124  PP133
PHARMACOKINETICS OF TOLPERISONE PHARMACOGENETICS OF THE HUMAN SEROTONIN
IN RELATION TO CYP2C19 GENOTYPES TRANSPORTER
J.-Y. Byeon* (KR) - J.-Y. LEE - J.-S. JEON - J.-E. Lee - S.-H. KIM - K. Münch* (DE) - J. Stump - H. Sticht - M. F. Fromm - O. Zolk
C.-G. JANG - S.-Y. LEE

 PP134
 PP126 ESOMEPRAZOLE USED AS A BOOSTER IN A HIV
IN-VITRO REACTIVITY OF DRUG-SPECIFIC ULTRARAPID CYP2C19 METABOLIZER TREATED
T-CELLS FROM A HLA-A*31:01 POSITIVE WITH VORICONAZOLE
CARBAMAZEPINE HYPERSENSITIVE PATIENT Y. Bouatou* (CH) - C. F. Samer - K. Ing Lorenzini - Y. Daali -
M. Lichtenfels* (GB) - D. J. Naisbitt - A. Alfirevic - K. B. Park - S. Daou - M. Fathi - M. Rebsamen - J. Desmeules - A. Calmy -
M. Pirmohamed M. Escher

 PP127  PP135
CYP4F2 AND APOE CONTRIBUTION PHARMACOMETABOLOMICS FOR INDIVIDUALIZED
IN ACENOCOUMAROL DOSING BASED ON TREATMENT OF ALCOHOLISM: HIGH SERUM
GENOTYPE: A COMPARISON OF TWO GLUTAMATE LEVEL IS ASSOCIATED WITH POSITIVE
ALGORITHMS RESPONSE TO ACAMPROSATE TREATMENT
H. Y. Tong* (ES) - A. M. Borobia - R. Lubomirov - C. Zegarra - D.-S. Choi* (US) - H. W. Nam - V. Karpyak
S. H. Lei - J. Frías - A. J. Carcas

 PP136
 PP128 GENETIC POLYMORPHISM OF CYP2D6
IMPACT OF VARIABILITY IN THE BRAIN-DERIVED SIGNIFICANTLY AFFECTS THE PHARMACOKINETICS
NEUROTROPHIC FACTOR (BDNF) GENE IN EATING OF TOLPERISONE
DISORDER PATIENTS J. Byeon* (KR) - J.-Y. LEE - J.-S. JEON - J.-E. LEE - S. H. KIM -
C. Gamero - I. Flores - J. A. Carrillo - A. Garcia-Herraiz - C.-I. CHOI - Y.-J. LEE - J.-W. BAE - C.-G. JANG - S.-Y. LEE
I. Gordillo - M. Monge - M. Jimenez - R. Rodriguez-Lopez -
G. Gervasini* (ES)  PP137

EFFECTS OF THE GENETIC POLYMORPHISMS
 PP129 OF HUMAN MULTIDRUG AND TOXIN
TIME-TO-ACHIEVE STABILITY OF ANTICOAGULATION EXTRUSION 1 (HMATE1/SLC47A1) TRANSPORTER
IS DECREASED IN ABCB1 MUTATED PATIENTS ON THE RENAL TUBULAR SECRETION
TREATED WITH ACENOCOUMAROL OF N1-METHYLNICOTINAMIDE
V. Rollason* (CH) - L. Gschwind - Y. Daali - F. Boehlen - R. Ogawa* (JP) - T. Mikami - M. Takahashi - H. Echizen
M. Rebsamen - C. Combescure - A. Matthey - P. Bonnabry -
P. Dayer - J. A. Desmeules  PP138

ANALYSIS OF CYP2D6 GENETIC POLYMORPHISMS
 PP130 IN MEXICAN MESTIZOS, LACANDONES AND
EVALUATION OF THE INFLUENCE OF CYTOCROME TZELTALES
P450 OXIDOREDUCTASE (POR) IN THE STABLE DOSE M. Lopez Lopez - E. M. Peñas-Lledó - O. Alberto - P. Dorado -
OF ACENOCOUMAROL T. Corona - A. Ochoa Morales - P. Yescas - M. E. Alonso
A. M. Borobia - H. Y. Tong* (ES) - R. Lubomirov - Vilatela - A. Llerena* (ES)
G. N. Almeida-Paulo - C. Zegarra - J. Frias - A. J. Carcas

 PP139
 PP131 ASSOCIATION OF ABCB1, ABCC2, CYP2C9
INTERACTION BETWEEN POLYMORPHISMS AND CYP2C19 POLYMORPHISM WITH PHENYTOIN
IN OCT2 AND MATE1 AND METFORMIN RENAL PLASMA CONCENTRATIONS
CLEARANCE A. Ortega Vázquez - N. Monroy Jaramillo - P. Dorado -
M. M. Hougaard Christensen* (DK) - R. S. Pedersen - I. F. Galindo - I. E. Juárez Martínez - H. Jung Cook -
T. Bjerregaard Stage - C. Brasch-Andersen - F. Nielsen - E. M. Peñas-Lledó - A. Ochoa Morales - M. E. Alonso
P. Damkier - H. Beck-Nielsen - K. Brosen Vilatela - A. Llerena* (ES) - M. Lopez Lopez
EACPT Poster Presentations → THURSDAY 29 August 2013 36
2013

 PP140  PP148
THE CONTRIBUTION OF PLATELET INFLUENCE OF CYP2C9 IVS8-109A>T POLYMOR-
GLYCOPROTEINS (GPIA C807T AND GPIBA C-5T) PHISM ON LOSARTAN OXIDATION IN HEALTHY
AND CYCLOOXYGENASE 2 (COX-2 G--765C) ECUADORIANS
POLYMORPHISMS TO PLATELET RESPONSE P. Dorado - A. Gallego - L. J. Beltrán - E. M. Peñas-LLedó -
IN PATIENTS TREATED WITH ASPIRIN E. Terán - A. LLerena*(ES)
S. Al-Azzam* (JO) - K. H. Alzoubi - O. Khabour - D. Tawalbeh -
O. Al-Azzeh  PP149

THE CEIBA COCKTAIL FOR DRUG HYDROXYLATION
 PP141 PHENOTYPING IN HISPANIC POPULATIONS
THE RELEVANCE OF PLATELET GLYCOPROTEIN F. De Andres - M. E. G. Naranjo - M. Sosa-Macías -
GP IIB/IIIA POLYMORPHISM TO ANTI-PLATELETS B. P. Lazalde Ramos - E. Tarazona-Santos - A. LLerena*
RESPONSE IN ACUTE CORONARY SYNDROME[ACS] (ES) and CEIBA Consortium.
O. A. Nayel* (EG) - M. I. Sobhey - A. M. Baraka - M. A. H. Al
Samak - S. I. Abdel Qauder
 PP151
PREVALENCE OF CARRIAGE CYP2C9, VKORC1
 PP142
AND CYP4F2 POLYMORPHISMS IN RUSSIAN
INFLUENCE OF THE CYP2D6 -1584C>G PROMOTER PATIENTS WITH HIGH THROMBOTIC RISK
POLYMORPHISM ON THE PHENOTYPE OF PRESCRIBED WARFARIN COMPARED WITH
DEBRISOQUINE IN HEALTHY VOLUNTEERS OTHER ETHNIC GROUPS
FROM CUBA AND NICARAGUA
D. Ivashchenko* (RU) - D. Sychev - I. Rusin - A. Grachev -
M. E. G. Naranjo* (ES) - P. Dorado - L. R. Calzadilla - T. Beloshickaya
M. Álvarez - R. Ramírez - E. M. Peñas-LLedó - B. Pérez -
I. González - A. LLerena and CEIBA Consortium.
 PP152
TENDENCY TO HIGHER ACTIVITY OF CYP3A5
 PP143
IN WOMEN WITH STILLBIRTH
IMPACT OF UGT1A4 GENOTYPE IN THE CLINICAL
RESPONSE TO LAMOTRIGINE IN PATIENTS WITH K. Zagorodnikova* (RU) - M. Kondrahina - J. Rustanovich -
EPILEPSY D. Kostyuchek

A. Ortega Vázquez - P. Dorado - S. Rojas Tomé - I. Iris
Martínez Juárez - H. Jung Cook - N. Monroy Jaramillo -  PP153
M. E. Alonso Vilatela - E. M. Peñas-Lledó - A. Llerena* (ES) - EVALUATION OF THE RELATIONSHIPS BETWEEN
M. Lopez Lopez ABCB1 C3435T AND G2677T/A POLYMORPHISMS

AND CLINICAL RESPONSE TO VENLAFAXINE
 PP144 IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
ASSESSING IN VIVO ENZYME GENETIC VARIATION G. Ozbey* (TR) - F. Cam Celikel - B. Elbozan Cumurcu -
IN THE PRESENCE OF TRANSPORTER EFFECT D. Kan - B. Yucel - E. Hasbek - F. Percin - C. Uluoglu

R. Chauhan* (GB) - N. Tsamandouras -
A. Rostami-Hodjegan  PP154

PERSONALISING HEALTH CARE: FEASIBILITY AND
 PP145 FUTURE IMPLICATIONS FOR ALL STAKEHOLDER
DISTRIBUTION OF GENETIC VARIANTS OF CYP2D6 GROUPS INCLUDING AUTHORITIES, PHYSICIANS
IN AMERINDIANS FROM NORTHWEST MEXICO AND PATIENTS
B. P. Lazalde-Ramos - C. Galaviz - M. Martínez-Fierro - B. Godman* (SE) - A. E. Finlayson - P. Cheema -
I. Garza Veloz - M. E. G. Naranjo - M. G. Sosa-Macias - E. Zebedin-Brandl - I. Gutiérrez-Ibarluzea - E. Diogene -
A. Llerena* (ES) K. Paterson - V. Vlahovic-Palcevski - L. L. Gustafsson

 PP146  PP155
ABCB1 C3435T POLYMORPHISM IS ASSOCIATED PREVALENCE OF GENE POLYMORPHISM SLCO1B1
WITH SUSCEPTIBILITY TO MAJOR DEPRESSION IN PATIENTS WITH DYSLIPIDEMIA AND SYSTEMIC
BUT NOT CLINICAL RESPONSE TO CITALOPRAM ATHEROSCLEROSIS IN RUSSIAN POPULATION
IN TURKISH POPULATION A. Sirotkina* (RU) - A. Khokhlov - E. Voronina

G. Ozbey* (TR) - B. Yucel - S. Erdogan Taycan - D. Kan -
N. Eren Bodur - T. Arslan - N. Yuksel - F. Percin - I. C. Guzey -  PP156
C. Uluoglu CYP2D6 GENOTYPES AND PREDICTION

OF METABOLIC PROFILES IN THE PORTUGUESE
 PP147 POPULATION: CLINICAL IMPLICATIONS
CYP2D6 GENETIC POLYMORPHISMS AMONG J. Albuquerque - C. Ribeiro - M. E. G. Naranjo - A. LLerena -
THREE COSTA RICAN POPULATIONS M. Grazina* (PT) and [Link] Consortium
C. Céspedes Garro* (CR) - G. Jiménez-Arce - M. E. [Link] - of the Ibero-American Network of Pharmacogenetics
R. Barrantes - A. LLerena and CEIBA Consortium and Pharmacogenomics RIBEF
EACPT Poster Presentations 37
2013


 PP157
CYP2C9 ALLELE FREQUENCIES AMONG THREE Poster Guided Tour
COSTA RICAN ETHNIC GROUPS COMPARED
TO HISPANIC POPULATIONS
C. Céspedes-Garro* (ES) - P. Dorado - G. Jiménez-Arce -

friday
M. E. [Link] - R. Barrantes - A. LLerena and CEIBA
Consortium

 PP159
C677T POLYMORPHISM OF METHYLENETETRA-
HYDROFOLATE REDUCTASE AND HOMOCYSTEINE
30 August
CONCENTRATION IN PATIENTS WITH ESSENTIAL
HYPERTENSION
N. B. Sidorenkova* (RU) - N. Terentyeva - G. Kostychenko -
2013
M. Plyasheshnikov

 12:30 – 13:30

 PP161
COMPARISON OF EFFECT OF RALOXIFENE ON THE
COAGULATION AND FIBRINOLYTIC SYSTEMS
BETWEEN MORNING AND EVENING DOSING
REGIMENS IN POST-MENOPAUSAL WOMEN WITH
OSTEOPOROSIS
K. Ushijima* (JP) - H. Ando - A. Fujimura

 PP162
THOROUGH QT STUDY WITH PONESIMOD,
A SELECTIVE S1P1 RECEPTOR MODULATOR
M. Hoch* (CH) - A. Vaclavkova - R. Stoltz - P. Brossard -
J. Dingemanse

 PP163
PBMC INCREASE SIRTUIN3 PROTEIN EXPRESSION
IN ACUTE ADAPTATION TO HYPOXIA IN HUMANS
A. Storka* (AT) - L. Wang - G. Führlinger - M. Wolzt

 PP164
DIPYRIDAMOLE DOES NOT LIMIT MYOCARDIAL
ISCHEMIA-REPERFUSION INJURY AFTER CORONARY
ARTERY BYPASS GRAFTING REGARDLESS AMPD1
GENOTYPE
S. El Messaoudi* (NL) - C. Wouters - H. V. Swieten -
P. Pickkers - E. Abbink-Zandbergen - A. Rasing-Hoogveld -
M. Bouw - N. Riksen - G. Rongen

 PP165
EVALUATION OF JNJ-26489112, A NOVEL
ANTIEPILEPTIC DRUG: A PLACEBO-CONTROLLED,
EXPLORATORY STUDY
D. Kasteleijn- Nolst Trenité* (IT) - N. A. Diprospero -
J. A. Moyer - J. Gambale - G. Pandina - L. Ford - S. Girgis -
L. Xi - J. Nye
EACPT Poster Presentations → FRIDAY 30 August 2013 38
2013

 PP166  PP177
EFFECT OF CARVEDILOL VERSUS CARVEDILOL/ INHIBITORY INTERACTION OF 125 DRUGS WITH
IVABRADINE COMBINATION ON HEART RATE, THE RENALLY EXPRESSED ORGANIC CATION
QUALITY OF LIFE, MORBIDITY AND MORTALITY TRANSPORTER OCT2: DEVELOPMENT OF A
IN PATIENTS WITH STABLE ISCHEMIC HEART CHEMOINFORMATICS-BASED MODEL TO PREDICT
FAILURE TRANSPORTER INHIBITION IN SILICO
T. Al Saadi* (OM) - M. Sallam - K. Al Hashmi - K. Münch* (DE) - J. Schwöbel - O. Zolk - R. Maas - L. Terfloth -
A. M. Elhawary M. F. Fromm

 PP167  PP178
INTEGRATED 14C STUDY DESIGNS TO ANTIEPILEPTIC DRUGS: PRESCRIBING PATTERNS
PROVIDE INTRAVENOUS PK AND HUMAN AND INTERACTION RISK IN GENERAL PRACTICE
MASS BALANCE AND METABOLISM DATA D. Italiano* (IT) - R. Ferrara - G. Trifirò - S. Gagliostro -
FROM A SINGLE PROTOCOL AND A SINGLE G. Starvaggi - C. Pagliaro - I. Lombardi - M. Tarì -
REGULATORY SUBMISSION A. Capuano - E. Spina - V. Arcoraci
L. Stevens* (GB) - I. Shaw
 PP179

 PP168 IDENTIFICATION OF DRUG-DRUG INTERACTIONS

A SURVEY ON A CLINICAL RESEARCH THROUGH A DIGITAL HEALTH SERVICE
INFORMATION PORTAL SITE FOR THE GENERAL S. Ussai* (IT) - A. Casetta - F. Pisa - G. Trillò - R. Petelin -
PUBLIC IN JAPAN F. Barbone - A. Degrassi - G. Giagnorio
E. Arita* (JP) - A. Ujihara - Y. Majima - I. Yamaguchi -
T. Genshin - K. Hoshi - Y. Nishibata - H. Yamasaki -  PP180
T. Watanabe - N. Tanabe
ROLE OF ORGANIC ANION TRANSPORTING
POLYPEPTIDES 1A2 AND 2B1 IN CELLULAR UPTAKE
OF NADOLOL
 PP169
S. Misaka* (DE) - F. Müller - H. Glaeser - J. König -
PIOGLITAZONE IN MILD TO MODERATE
M. F. Fromm
ULCERATIVE COLITIS: A PLACEBO CONTROLLED
RANDOMIZED TRIAL
B. Medhi* (IN) - S. Kaur - S. C. Sarangi - A. Prakash -  PP181
U. Dutta - R. KOCHHAR EVALUATION OF THE INTERACTION BETWEEN
METHOTREXATE AND PROTON PUMP INHIBITORS
USING HUMAN OAT1 AND OAT3 HEK TRANSFECTED
 PP172
CELLS
SHORT-TERM IMPACT OF BARIATRIC SURGERY R. Chioukh - M.-S. Noel-Hudson - S. Ribes - N. Fournier -
ON OBESITY ASSOCIATED DIABETES MELLITUS L. Becquemont - C. Verstuyft* (fr)
C. Kumana* (CN) - B. M. Cheung - K. Tan

 PP183
 PP173 EFFECT OF RITONAVIR, KETOCONAZOLE
CYTISIN AMIDOPHOSPHATE SHOWS AND RIFAMPIN ON INTESTINAL AND HEPATIC
HEPATOPROTECTIVE EFFECT CYTOCHROME P450 3A ENZYMES IN HEALTHY
T. Nurgozhin* (KZ) - A. Gulyaev - A. Gazaliyev ASIAN ADULTS
K.-Y. Seng - K. H. Hee - L. S.-U. Lee* (SG)

 PP175
EVIDENCE OF DRUG-DRUG INTERACTIONS  PP186
THROUGH UPTAKE AND EFFLUX TRANSPORT THE ANALYSIS OF INTERACTION OF WARFARIN
SYSTEMS IN RAT HEPATOCYTES: IN THE REAL CLINICAL PRACTICE
IMPLICATIONS FOR CELLULAR CONCENTRATIONS R. Barakanova* (KG) - U. Tilekeeva
OF COMPETING DRUGS
Y. Daali* (CH) - P. Millet - P. Dayer - C. Pastor
 PP189
A PHYSIOLOGICALLY-BASED MECHANISTIC
 PP176 PHARMACOKINETIC MODEL TO ASSESS
COMPARISON OF INHIBITORY DURATION THE METABOLISM OF OXYCODONE IN HEALTHY
OF GRAPEFRUIT JUICE ON ORGANIC ANION- VOLUNTEERS: INTERPLAY BETWEEN CYP3A
TRANSPORTING POLYPEPTIDE AND CYP3A4 AND 2D6 INHIBITION
S. Tanaka* (JP) - S. Uchida - S. Miyakawa - N. Inui - N. Marsousi* (CH) - Y. Daali - H. Humphries - L. Almond -
K. Takeuchi - H. Watanabe - N. Namiki P. Dayer - J. Desmeules - C. Samer
EACPT Poster Presentations → FRIDAY 30 August 2013 39
2013

 PP191  PP199
INFLUENCE OF VERAPAMIL ON THE INTRACELLULAR CONCENTRATION OF DARUNAVIR
PHARMACOKINETICS OF OXCARBAZEPINE AS AN INDICATOR FOR THE CLINICAL EFFICACY
AND 10-HYDROXYCARBAZEPINE ENANTIOMERS IN HIV PATIENTS
IN HEALTHY VOLUNTEERS D. Nagano* (JP) - T. Araki - K. Yanagisawa - T. Hayashi -
N. D. J. Antunes* (BR) - L. Wichert-Ana - E. B. Coelho - Y. Ogawa - Y. Nojima - T. Nakamura - K. Yamamoto
O. Della Pasqua - V. Alexandre Junior - O. M. Takayanagui -
V. L. Lanchote
 PP200
METABOLIC PROCESS OF VORICONAZOLE
 PP192 TO ITS N-OXIDE IS SATURABLE IN CLINICAL
PHARMACOKINETICS OF SELEXIPAG IN SUBJECTS DOSE RANGE
WITH SEVERE RENAL IMPAIRMENT OMPARED T. Yamada* (JP) - Y. Mino - T. Yagi - T. Naito - J. Kawakami
TO HEALTHY SUBJECTS
N. Fischer* (CH) - H. Cruz - S. Bruderer - M. Petersen-
Sylla - A. Halabi - J. Dingemanse  PP201

AN OPEN-LABEL, RANDOMIZED, SINGLE-CENTRE,

FOUR-WAY CROSSOVER STUDY TO EVALUATE
 PP193 THE PHARMACOKINETICS OF SINGLE, ORAL DOSES
SIMULTANEOUS LC-MS/MS QUANTIFICATION OF RETIGABINE/EZOGABINE IN HEALTHY ADULT
OF P-GLYCOPROTEIN AND CYTOCHROME P450 TAIWANESE SUBJECTS
PROBE SUBSTRATES AND THEIR METABOLITES M. Buraglio* (GB)
IN DRIED BLOOD SPOTS
M. Bosilkovska* (CH) - J. Deglon - C. Samer - B. Walder -
P. Dayer - J. Desmeules - C. Staub - Y. Daali  PP202

CANCER CACHEXIA RAISES THE PLASMA

CONCENTRATION OF OXYMORPHONE THROUGH
 PP194 THE REDUCTION OF CYP3A BUT NOT CYP2D6
PHARMACOKINETICS OF SELEXIPAG IN SUBJECTS IN OXYCODONE-TREATED PATIENTS
WITH MILD, MODERATE, OR SEVERE HEPATIC T. Naito* (JP) - M. Tashiro - T. Ishida - K. Ohnishi -
IMPAIRMENT COMPARED TO HEALTHY SUBJECTS J. Kawakami
N. Fischer* (CH) - P. Kaufmann - S. Bruderer - I. Ulč -
J. Dingemanse
 PP203
WHOLE BLOOD CANNABINOID PHARMACOKINETIC
 PP195 PARAMETERS IN HEAVY AND OCCASIONAL
VORICONAZOLE ADJUSTMENT FROM TWICE SMOKERS. DO ORAL FLUID CANNABINOID
TO THREE TIMES DAILY IN CYSTIC FIBROSIS MEASUREMENTS CORRELATE WITH WHOLE BLOOD
LUNG TRANSPLANT PATIENTS DATA IN HEAVY SMOKERS?
L. Tanneau - G. Deslandes* (FR) - T. Lepoivre - D. Boutoille - M. Fabritius* (CH) - E. Lauer - H. Chtioui - M. Appenzeller -
R. Bouquié - E. Dailly - P. Jolliet P. Mangin - C. Staub - C. Giroud

 PP196  PP204
ENANTIOSELECTIVE METABOLISM METHADONE KINETICS AND CORRECTED
OF VENLAFAXINE IN HEALTHY VOLUNTEERS QT TIME DURING HAEMODIALYSIS IN FOUR
AND IN PATIENTS WITH PSORIASIS METHADONE MAINTENANCE TREATMENT
V. L. Lanchote* (BR) - A. L. P. C. Godoy - C. D. Silva Souza - PATIENTS WITH END-STAGE RENAL FAILURE
E. B. Coelho - A. Rocha - E. Tozatto M. S. Opdal* (NO) - M. Arnesen - K. Sayed - S. Sagedal -
K. Gjesdal - L. D. Müller - M. Kringen - O. Brørs - P. Krajci

 PP197
THERAPEUTIC DRUG MONITORING OF VANCOMYCIN  PP205
AND AMINOGLYCOSIDES IN AN INTENSIVE CARE COMPARISON OF PHARMACODYNAMIC EFFECT
UNIT, A RETROSPECTIVE STUDY OF TWO DIFFERENT MODIFIED-RELEASE ORAL
K. R. Ing Lorenzini* (CH) - C. Samer - J. Pugin - S. Harbarth - DILTIAZEM FORMULATIONS
P. Bonnabry - M. Fathi - P. Dayer - J. Desmeules M. Bogiel* (PL) - M. Pawłowska - J. Duda - E. Sieradzki

 PP198  PP207
PHARMACOKINETICS OF IMIPENEM IN THE PHARMACOKINETICS OF SUGAMMADEX 16 MG/KG
TREATMENT OF NOSOCOMIAL PNEUMONIA: IN CHINESE SUBJECTS
COMPARISON OF 0.5 HR AND 3 HR INFUSION P.-J. de Kam* (US) - J. Hou - Z. Wang - W. H. Lin - P. Grobara -
H. Suchánková* (CZ) - M. Lipš - M. Šiller - J. Strojil - K. Urbánek M. van den Heuvel
EACPT Poster Presentations → FRIDAY 30 August 2013 40
2013

 PP208  PP217
DEOXYCHOLIC ACID AS A MODIFIER OF THE CORRELATION BETWEEN IN VITRO TESTS
BLOOD BRAIN BARRIER PERMEATION IN RAT FOR BLOOD BRAIN BARRIER PENETRATION
M. Lalic-Popovic* (RS) - S. Golocorbin-Kon - V. Vasovic - WITH IN VIVO GLICLAZIDE PENETRATION
B. Milijasevic - M. Mikov M. Lalic-Popovic* (RS) - V. Vasovic - H. Al-Salami -
S. Golocorbin-Kon - B. Milijasevic - M. Mikov


 PP209 MODEL-BASED ANALYSIS OF THE
PHARMACOKINETICS OF A MODIFIED RELEASE  PP219

FORMULATION OF PARACETAMOL AFTER THIOPURINE METABOLITES ARE USEFUL

TWICE DAILY DOSING AND POTENTIAL IN PREDICTING AZATHIOPRINE RESISTANCE
IMPLICATIONS FOR THE RISK OF HEPATOTOXICITY IN PEDIATRIC IBD PATIENTS
IN OSTEOARTHRITIS PATIENTS T. V. A. Nguyen - T. M. H. Nguyen - A. Lachaux - R. Boulieu*
O. Della Pasqua* (GB) - K. Bergman - J. de Jongh (FR)


 PP220
 PP210
THE RISK OF BIRTH DEFECTS FOLLOWING
PHARMACOKINETICS AND PHARMACODYNAMICS
EXPOSURE TO NITROFURANTOIN DURING FIRST
MODELING TO OPTIMIZE DOSAGE REGIMENS
TRIMESTER
OF SULBACTAM
O. J. Goldberg* (IL) - D. Landau - G. Koren - E. Lunenfeld -
S. Jaruratanasirikul* (TH) - W. Wongpoowarak -
I. Matok - A. Levy and BeMORE collaboration (Ben-Gurion
N. Aeinlang - M. Jullangkoon
Motherisk Obstetric Registry of Exposure collaboration)

 PP211  PP221
PIPERINE INCREASES PLASMA DOMPERIDONE DRUG USE IN THE PAEDIATRIC WARDS IN
CONCENTRATIONS IN THE RAT DENMARK – A NATIONWIDE STUDY WITH
M. Alhumayyd* (SA) - I. Bukhari - A. Almotrefi FOCUS ON LEGISLATION
S. S. Haslund-Krog* (DK) - R. Mathiasen - H. Rolighed

Christensen - H. Holst
 PP212
BIOAVAILABILITY OF DIGOXIN TABLETS,
LOW THERAPEUTIC INDEX DRUG, DETERMINED  PP222
BY EMIT THERAPEUTIC DRUG MONITORING
J. Duda* (PL) - M. Pawłowska - M. Bogiel - OF DAPTOMYCIN: A RETROSPECTIVE
B. Tejchman-Małecka - E. Sieradzki MONOCENTRIC ANALYSIS
C. Reiber - O. Senn - D. Müller - G. A. Kullak-Ublick -
N. Corti* (CH)
 PP213
CORRELATION OF DISSOLUTION DATA WITH
 PP223
CLINICAL EFFICACY OF TWO LAMOTRIGINE
TABLET FORMULATION PERCEPTIONS TOWARDS BENZODIAZEPINE
DISCONTINUATION IN NURSING HOMES
M. Lalic-Popovic* (RS) - S. Golocorbin-Kon - V. Vasovic -
B. Milijasevic - M. Mikov J. Bourgeois* (BE) - M. Elseviers - M. Azermai - L. Van Bortel -
M. Petrovic - R. Vander Stichele

 PP214
 PP224
TACROLIMUS BLOOD CONCENTRATION IN PATIENTS VIEWS OF CLINICAL AND NON-CLINICAL
SUBJECTED TO RENAL TRANSPLANTATION: PROFESSIONALS ON INFORMATION ABOUT
THE INFLUENCE OF GENDER OLDER PATIENTS NEEDED FOR RATIONAL
N. Rancic - N. Vavic - A. Kovacevic* (RS) - V. Dragojevic- DRUG PRESCRIPTION AT TIME OF AUTHORISATION
Simic - B. Draskovic-Pavlovic - D. Bokonjic - L. Ignjatovic - E. Beers* (NL) - A. C. Egberts - H. G. Leufkens - P. A. Jansen
M. Mikov


 PP226
 PP215 AVAILABLE AND CLINICALLY APPLICABLE
PHARMACOKINETIC STUDY OF GANCICLOVIR (GCV) INFORMATION FOR RATIONAL PRESCRIBING
AFTER SINGLE AND MULTIPLE DOSE IN HEMATO- TO OLDER PATIENTS IN EUROPEAN AND AMERICAN
POIETIC STEM CELL TRANSPLANT (HSCT) PATIENTS HANDBOOKS
WITH CYTOMEGALOVIRUS (CMV) INFECTION J. L. Boer - E. Beers* (NL) - T. C. Egberts - H. G. Leufkens -
S. M. Awada* (LB) P. A. Jansen
EACPT Poster Presentations 41
2013


 PP227
CHRONIC TREATMENT WITH PRAVASTATIN Poster Guided Tour
IMPROVES THE IMPAIRED NITRIC
OXIDE – MEDIATED NEUROGENIC AND
ENDOTHELIUM-DEPENDENT RELAXATION

Saturday
OF CORPUS CAVERNOSUM IN AGED RATS
S. Dalaklioglu - P. Sahin - A. Tasatargil* (TR) -
C. Celik-Ozenci

31 August

 PP228
ADVERSE REACTIONS IN CHILDREN ARE NOT
THE SAME IN ADULTS: ANALYSIS OF SPONTANEOUS
REPORTS IN 2011-2012 IN CRIMEA, UKRAINE
O. V. Matvieiev* (UA)
2013

 PP229
OBSERVATIONS ON THE OXALIS PERDICARIA
(MOLINA) BERTERO IN CHILDREN WITH
THE PERSISTENT MALNUTRITION DIARRHEA:
 10:30 – 11:15
RANDOMIZED CONTROLLED CLINICAL TRIAL
M. A. H. Mollik* (BD)

 PP230
PATTERN OF PARENTERAL DRUG PRESCRIPTION
FOR CHILDREN UNDER THE AGE OF 6 IN TURKEY  PP231
B. Donertas - A. Gelal* (TR) - A. Alkan - S. Mollahaliloglu - ACUTE HUMAN TOXICITY OF THIOPURINES,
A. Akici MYCOPHENOLATE AND SIROLIMUS
C. Gregoriano - A. Ceschi - C. Rauber-Lüthy - H. Kupfer-
schmidt - S. Krähenbühl - A. Taegtmeyer * (CH)

 PP232
ACUTE TOXICITY PROFILE OF PIPAMPERONE
IN OVERDOSE: A CONSECUTIVE CASE SERIES
K. E. Hofer* (CH) - C. Rauber-Lüthy - H. Kupferschmidt -
G. A. Kullak-Ublick - A. Ceschi

 PP233
CYP1A ACTIVITY AFTER CHRONIC EXPOSURE
TO DIOXINS FROM A WASTE INCINERATOR
C. Samer* (CH) - F. Doffey-Lazeyras - O. Sorg -
J.-H. Saurat - P. Dayer - Y. Daali - J. Desmeules

 PP234
INTOXICATION WITH ATYPICAL ANTIPSYCHOTICS
IN YOUNG CHILDREN: A MULTICENTRE ANALYSIS
OF POISONS CENTRES DATA
M. Meli* (CH) - C. Rauber-Lüthy - P. Hoffmann-Walbeck -
H.-J. Reinecke - D. Prasa - U. Stedtler - E. Färber - G. Dieter -
H. Kupferschmidt - G. A. Kullak-Ublick - A. Ceschi

 PP237
EVALUATION OF THE EFFECT OF DIMETHOATE
INTOXICATION ON MALE RAT REPRODUCTIVE
PERFORMANCES
J. M. El-Medany* (EG) - A. M. El-Medany - A. A. Guemei -
Y. A. Bassioni
EACPT Poster Presentations → SATURDAY 31 August 2013 42
2013

 PP238  PP255
SYNTHESIS OF THE FIVE BANGLADESHI IFN-GAMMA INTERFERE THE EFFECT OF BETA-2
UNANI MEDICINES DERIVATIVES: IN VITRO STUDIES AGONIST ON TNF-ALPHA INDUCED CXCL10 THROUGH
OF THEIR PHARMACOLOGICAL ACTIVITIES CREB PHOSPHORYLATION IN HASM CELLS
M. A. H. Mollik* (BD) S. Jindarat* (TH) - D. L. Clarke - R. Clifford - A. E. John -

A. J. Knox
 PP239
SUSCEPTIBILITY OF LEPTOSPIRA TO XANTHONES
 PP256
AND SYNERGISTIC EFFECTS WITH ANTIBIOTICS
COMPARATIVE STUDY BETWEEN ANGIOTENSIN
C. Mekseepralard* (TH) - W. Seesom - S. Suksumran -
INHIBITORS & THEIR RECEPTOR BLOCKERS
P. Ratananukul - T. Kammee - W. Sukhumsirichart
ON ULCERATIVE COLITIS IN RATS
J. H. Elmedany* (SA) - A. H. El-Medany - H. I. Hagar
 PP240

PHARMACEUTICAL QUALITY OF GENERIC
LEVODOPA/BENSERAZIDE PRODUCTS  PP257
G. L. Vital-Durand* (CH) - I. Arnet - U. E. Gasser - A. Fischer CHLOROGENIC ACID AS POTENTIAL

ANTI-INFLAMMATORY ANALGESIC AGENT
 PP241 A. M. El-Medany* (EG) - Y. A. Bassiouni - M. M. Khattab -
POTENTIAL EFFECT OF THE MEDICINAL PLANTS; A. A. Mahesar
CALOTROPIS PROCERA, FICUS ELASTICA
AND ZINGIBER OFFICINALE AGAINST SCHISTOSOMA
MANSONI IN MICE  PP259

S. S. Botros* (EG) - S. H. Seif el-Din - N. M. El-Lakkany - THE ABILITY OF ANTI-S100 ANTIBODIES

M. A. Mohamed - M. M. Hamed - O. Sterner TO AMELIORATE THE SEVERITY OF EXPERIMENTAL
ALLERGIC ENCEPHALOMYELITIS IN WISTAR RATS
 PP243 J. L. Dugina* (RU) - I. N. Abdurasulova - I. A. Ertuzun -
THE POTENTIAL ANTICANCER EFFECT OF AZO DYES O. I. Epstein
L. Harmse* (ZA) - S. Moch - H. Motau

 PP261
 PP244
UTILIZATION OF TRIPTANES IN SWEDEN;
THERAPEUTIC AND SUPRA-THERAPEUTIC ANALYSES OF OVER THE COUNTER
INTRAVENOUS DOSES OF MAVOGLURANT (AFQ056) AND PRESCRIPTIONS SALES
DO NOT PROLONG THE QTC INTERVAL IN HEALTHY
M. Von Euler* (SE) - S. Keshani - K. Baatz - B. Wettermark
SUBJECTS

M. Ufer* (CH) and A. Tisserant, A. Dodman, E. Voltz,
A. Salunke, R. Woessner, A. Sagkriotis, P. Jordaan,  PP262
E. Legangneux CAN AUTHORITIES TAKE FULL ADVANTAGE OF THE

AVAILABILITY OF GENERIC ATYPICAL ANTIPSYCHOTIC
 PP245 DRUGS? IMPLICATIONS FOR THE FUTURE
IN-VITRO BIOASSAY OF 1,5 - DIMETHYL CITRATE B. Godman* (SE) - M. Persson - J. Miranda - C. Barbui -
MONOHYDRATE; A COMPOUND ISOLATED M. Bennie - K. Bennett - A. Bucsics - S. Simoens - C. Zara -
FROM THE FRUIT OF MANGIFERA INDICA L. L. Gustafsson
(ANACARDIACEAE)
F. Khan* (NG) - E. olowononi - M. Garba - A. lawal
 PP263

 PP248 IMPORTANCE OF TDM, PHENOTYPING AND GENO-

MELITOR® - REGULATORY ISSUES AS PREREQUISITE TYPING DURING INTOXICATION WITH VENLAFAXINE
FOR PUTTING DRUG ON THE MARKET I. Kacirova* (CZ) - M. Grundmann - R. Urinovska - P. Silhan
V. Stanimirovic* (RS) - D. NIKOLIC - A. Nikolic -
B. Stanimirovic - M. Lisicic
 PP264
4-METHYLESCULETIN A DUAL ACTING INHIBITOR
 PP249
OF ACETYLCHOLINESTERASE AND XANTHINE
BRINAVESS® - ARGUMENTS OF OXIDASE
REGULATORY SUSPENSION IN SERBIA
T. Shirole* (IN) - E. Martis - D. Makhija - R. Pissurlenkar -
V. Stanimirovic* (RS) - D. NIKOLIC - A. Nikolic - A. Jagtap - E. Coutinho
B. Stanimirovic - M. Lisicic

 PP252  PP265
ETHICS OF RELATIONSHIPS IN THE SPHERE ATTENUATION OF ALUMINIUM INDUCED
OF PHARMACEUTICAL SERVICES NEURODEGENERATION BY 4-METHYLESCULETIN
E. Abdukakharova* (KG) - A. Zurdinov T. Shirole* (IN) - D. Makhija - A. Jagtap
EACPT Poster Presentations → SATURDAY 31 August 2013 43
2013

 PP266  PP277
IMPROVED BEHAVIOUR OF APPSW 2576 ALZHEIMER’S INCREASE IN MORPHINE ANALGESIC EFFECT WHEN
DISEASE TRANSGENIC MICE ON LONG TERM CO-ADMINISTRATED WITH BILE ACID DERIVATES
SUPPLEMENTATION OF FIGS IN THEIR DIET V. Vasovic* (RS) - S. Vukmirovic - M. Mikov - I. Mikov -
M. Essa - S. Subhash - R. Vaishnav* (OM) and Ageing Z. Budakov - N. Stilinovic - B. Milijasevic
and Dementia Research Group, Sultan Qaboos University,
Muscat, Oman.
 PP278
BILE ACID INDUCED CHANGES IN THE EXPRESSION
 PP268
OF MIRNAS AND GENES INVOLVED IN DRUG
DRUG-INDUCED LONG QT IN ADULT PSYCHIATRIC METABOLISM AND DISPOSITION
INPATIENTS: THE 5-YEAR CROSS-SECTIONAL J. Mwinyi* (CH) - W. E. Thasler - G. A. Kullak-Ublick
ESOP STUDY
F. R. Girardin* (CH) - M. Gex-Fabry - P. Berney - D. Shah -
J.-M. Gaspoz - P. Dayer  PP279
CARDIO-HEPATIC SYNDROME AND THERAPEUTIC
EFFICACY OF NAD-CONTAINING DRUG
 PP269
INTEREST OF GENOTYPE ASSESSMENT N. V. Gongadze* (GE) - M. A. Rogava - T. M. Bochorishvili -
IN ANTIDEPRESSANT TREATMENT FAILURE T. D. Kezeli - N. P. Mitagvari - M. K. Chipashvili - N. M. Dolidze -
IN PSYCHIATRIC PATIENTS: A CASE REPORT G. V. Sukoyan

F. Rodieux* (CH) - A. Zavodnik - Y. Daali - V. Rollason -
K. Gomez-Padra - N. Fuertes-Fernandez - J. Desmeules -  PP280
M. Besson BLOOD LEVELS OF CYCLOSPORINE A AND ITS FIRST

LINE METABOLITES DURING AN EARLY FASE AFTER
 PP270 RENAL TRANSPLANTATION IN PATIENTS WITH
COMPUTATIONAL MODELING OF DRAVET SYNDROME NORMAL AND DELAYED GRAFT FUNCTION
P. Kurbatova* (FR) - P. Benquet - F. Wendling - C. Cornu - M. Grundmann* (CZ) - P. Halvova - H. Brozmanova -
R. Guerrini - A. Kaminska - O. Dulac - G. Pons - R. Nabbout - J. Dedochova - A. Martinek
C. Chiron - P. Nony

 PP281
 PP271 INTRAVENOUS STREPTOMYCIN DOSING REGIMEN
NOVEL THERAPEUTIC STRATEGY TO PREVENT IN A PATIENT UNDERGOING HEMODIALYSIS:
CHEMOTHERAPY-INDUCED PERSISTENT SENSORY PLASMA LEVEL MONITORING AND PHARMACO-
NEUROPATHY BY TRPA1 BLOCKADE KINETIC SIMULATION
G. Trevisan - S. Materazzi - C. Fusi - A. Altomare - G. Aldini - H. Chtioui* (CH) - D. Zbinden - O. Manuel - J. Entenza -
R. Patacchini - P. Geppetti - R. Nassini* (IT) L. A. Decosterd - T. Buclin

 PP272  PP282
MIGRAINE AND PARTHENOLIDE INHIBITION THE ROLE OF CBS AND H2S IN THE INDUCTION
OF TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1 OF TORPOR AND ORGAN PRESERVATION DURING
S. Materazzi - S. Benemei* (IT) - C. Fusi - G. De Siena - HIBERNATION
G. Trevisan dos Santos - G. Dussor - F. Pollastro - G. J. Dugbartey* (NL) and Prof. Dr. Robert H. Henning
R. Patacchini - G. Appendino - P. Geppetti - R. Nassini

 PP283
 PP273
MOTOR AND BEHAVIORAL CHANGES IN MICE
EFFECT OF THE GABAA LIGANDS CLOBAZAM
WITH CISPLATIN-INDUCED ACUTE RENAL FAILURE
AND CLONAZEPAM ON THE MODULATION OF PAIN
A. Ramkumar* (OM) - T. T. Madanagopal - S. Al-Abri -
TRANSMISSION IN HUMANS: A PK-PD STUDY
M. I. Waly - M. Tageldin - M. Fahim - A. Nemmar - B. H. Ali
M. Besson* (CH) - A. Matthey - D. Youssef - P. Vuillemier -

M. Curatolo - P. Dayer - H. U. Zeilhofer - J. Desmeules

 PP284
 PP274 EFFECT OF DIESEL EXHAUSTS PARTICLES
MEMANTINE PREVENTS THE DEVELOPMENT OF ON CISPLATIN-INDUCED TOXICITY
NEUROPATHIC PAIN WHEN GIVEN BEFORE SURGERY ON HUMAN KIDNEY CELLS, AND THE INFLUENCE
G. Pickering* (FR) - V. Morel - L. Terrail OF CURCUMIN THEREON
B. H. Ali* (OM) - M. I. Waly - A. Nemmar
 PP275
CHITOSAN/POLYMER NANOPARTICULATE
CONTROLLED RELEASE SYSTEM FOR IBUPROFEN
B. I. Tamba* (RO) - V. Streinu - D. Iurea - M. Popa -
J.-F. Chailan - C. Peptu
EACPT Exhibition floor plan 44
2013

EACPT BPS Novartis

Elsevier

Coffee Breaks
Wiley

Congress Centre floor plan

EACPT Congress Centre floor plan 45
2013
EACPT Congress Centre – Access map 46
2013

 Centre
International 17 rue de Varembé
CH – 1211 Genève 20

de Conférence Tel.   +41 (0)22 791 91 11

Fax   +41 (0)22 791 90 64

Genève (CICG)

 Public Transport
from the Cornavin Train Station:
Public Transport
from Geneva Airport (Cointrin):

• Bus n°5: Stop “Vermont” • Bus n°5: Stop “Vermont”

• Bus n°8: Stop “UIT” • Bus n°28: Stop “Nations”

• Tram n°15: Stop “Nations”